

## Call for proposals 2024

### Modulation of brain ageing through nutrition and healthy lifestyle (NutriBrain)

#### Call Text

#### DEADLINES

January 15, 2024 (16:00 CET) - SUBMISSION OF PRE-PROPOSALS

27 May, 2024 (16h00 CEST) - SUBMISSION OF INVITED FULL-PROPOSALS

Link to electronic proposal submission

<https://ptoutline.eu/app/era4healthnutribrain>

For further information, please visit us on the website: <https://era4health.eu/>

or contact the Joint Call Secretariat (JCS):

Italian Ministry of University and Research

Dr. Aldo Covello and Dr. Sara Cella

[nutribrain@mur.gov.it](mailto:nutribrain@mur.gov.it)

---

#### History of modifications :

10/11/2023 :

- Modification of IT-MOH national annex : in «Submission of the proposal at the national level » the link to download the pre-eligibility form has been updated : [https://www.salute.gov.it/imgs/C\\_17\\_pagineAree\\_4441\\_0\\_file.pdf](https://www.salute.gov.it/imgs/C_17_pagineAree_4441_0_file.pdf)
- Modification of ISCIH National Annex
- Inclusion of TUBITAK (Turkey) and LCS (Latvia) as participating funding organisations. Latvia has been included among the under-represented countries.

14/11/2023 :

- Inclusion of HRB (Ireland) as participating funding organisation
- Modification to ANR National Annex :in « Eligibility of costs, types and their caps » the overhead rate has been changed into 13,5%

## Content

|   |    |
|---|----|
| Aim and ambition of ERA4Health.....                                   | 5  |
| Rationale.....  | 5  |
| Aim of the call.....  | 6  |
| Expected Impact.....  | 8  |
| General conditions for application.....                               | 8  |
| Participating countries and respective funding organisations.....     | 9  |
| Application .....   | 10 |
| ELIGIBILITY CRITERIA .....  | 10 |
| Size of the consortium.....   | 10 |
| Financial and legal modalities .....                                  | 12 |
| Submission of joint proposals .....                                   | 12 |
| Further information.....  | 13 |
| Evaluation and decision.....  | 13 |
| Eligibility check and evaluation procedure .....                      | 13 |
| Eligibility check and evaluation of pre-proposals (first step) .....  | 13 |
| Eligibility check and evaluation of full proposals (second step)..... | 14 |
| Evaluation Criteria .....   | 14 |
| Scoring system.....   | 15 |
| Rebuttal stage .....  | 16 |
| PRP meeting .....   | 16 |
| Ethical clearance.....  | 16 |
| Decision .....  | 16 |
| Redress procedure .....   | 16 |
| Admissibility of appeals.....   | 17 |
| Procedure .....   | 17 |
| Responsibilities, Reporting requirements and Dissemination.....       | 17 |
| Consortium Agreement.....   | 17 |
| Open Science .....  | 18 |
| Progress report.....  | 18 |
| Communication .....   | 18 |
| Support for Early Career Scientists .....                             | 19 |
| Confidentiality .....   | 19 |
| General Data Protection Regulation .....                              | 19 |
| ERA4Health Responsible Research and Innovation (RRI) Guidelines ..... | 21 |

|   |    |
|---|----|
| What is RRI and why do we need it? .....            | 21 |
| What is ERA4Health’s approach to RRI? .....         | 21 |
| How should you include RRI in your project? .....   | 22 |
| But what should you actually do? .....              | 23 |
| How does ERA4Health support and evaluate RRI? ..... | 25 |
| ANNEX I National/Regional Annexes.....              | 27 |

## Aim and ambition of ERA4Health

The Partnership “Fostering a European Research Area for Health” (ERA4Health) aims at establishing a flexible and effective coordination between funding organisations in the European Research Area (ERA) for Health and Well-being. This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing European Public Health Needs.

The general objective of ERA4Health is to reach an effective joint approach and generate knowledge and products (e.g. preventive guidelines, medical protocols) in the identified research areas as outlined in ERA4Health Strategic Research and Innovation Agenda (SRIA)<sup>1</sup>. To achieve this, a comprehensive network will be created which aims at strengthening and expanding the existing conducive eco-system.

In this light, ERA4Health gathers public funders of health research in the European Research Area including the European Commission that jointly identify and implement a common funding strategy in priority areas to advance health research and develop innovation.

ERA4Health has 4 specific objectives:

- SO1. Support relevant medical research including clinical fields and intervention areas (prevention, diagnosis, treatment),
- SO2. Improve the utilisation of existing health technologies in clinical practice,
- SO3. Build capacity, in particular in conducting IICs at European scale,
- SO4. Implement and advance the practice of Responsible Research and Innovation (RRI) across the breadth of the programme.

## Rationale

Increased lifespan, in combination with environmental and lifestyle modifications, is among those factors responsible for the increased prevalence of cognitive disorders of different severity, from mild cognitive impairment (MCI) till overt dementia (such as Alzheimer’s disease). Due to demographic changes in Western societies, age-related diseases such as dementia are assuming a societal challenge in terms of public health and health care. In addition, maintaining cognitive abilities in old age enables people to remain independent for as long as possible and increases the number of years with a high quality of life.

To date, there is no proven disease-modifying treatment for cognitive impairment during ageing, so the main focus is on prevention and early detection. Epidemiological studies suggest that obesity, inadequate nutrition, protein energy malnutrition (PEM), poor sleep, and physical inactivity increase the risk of cognitive impairment, although there is still limited evidence of how better nutrition and increased physical activity could slow down brain ageing and lower the risk of cognitive impairment. Thus, increasing knowledge on promoting changes in lifestyle in pre-symptomatic and predementia stages, implemented in evidenced based multimodal interventions, are highly needed since they may have the potential for delaying a high proportion of dementia worldwide.

---

<sup>1</sup>[https://ec.europa.eu/info/sites/default/files/research\\_and\\_innovation/funding/documents/ec\\_rtd\\_he-partnerships-era-for-health.pdf](https://ec.europa.eu/info/sites/default/files/research_and_innovation/funding/documents/ec_rtd_he-partnerships-era-for-health.pdf)

## Aim of the call

The aim of the call is to support transnational research projects that focus on the improvement of cognitive brain ageing through nutrition and other lifestyle factors. Thereby it enables scientists from different countries to build a valuable collaboration on interdisciplinary research projects based on complementarities and sharing of expertise in the field of brain ageing, its related disorders, nutrition and lifestyle factors.

Research projects should gain further insights into the modulation of brain aging by lifestyle factors and/or pilot test interventions based on the existing evidence in the literature or upscale existing pilot interventions that will help to lower the risk of cognitive impairment manifestations related to a pathological brain ageing.

At least one of the following lifestyle factors should be investigated: nutrition (particularly improvements in dietary pattern), physical activity, sleep pattern (quantity, quality and timing), social interaction and stress.

Researchers should provide a public health approach for health promotion and disease prevention considering large population groups such as age cohorts or relevant subgroups.

Proposals shall include one of the following approaches, such as:

- Pilot test interventions that will help to lower the risk of cognitive impairment manifestations related to a pathological brain ageing
- Upscaling of existing pilot interventions that will help to lower the risk of cognitive impairment manifestations related to pathological brain ageing

Proposals may be supplemented by one of the following approaches, such as:

- Mechanistic / experimental research focusing on how specific lifestyle factors influence brain ageing
- Translational research that will establish proof of concept, in order to support the development of effective health-improvement strategies and/or solutions to promote a healthy brain.

In addition, the following points should be considered:

- Research proposals may focus on specific population groups, e.g., those living with obesity and/or sarcopenia or with specific phenotypes, who may benefit from particular dietary and/or physical activity and life-style interventions, but can also focus on broader populations groups.
- For projects focussing on the prevention of cognitive impairment before the onset of clinical symptoms, the target group is not necessarily elderly, but may include also adults of other age groups.
- Applicants should make use of existing biobanks and cohorts, if applicable. Otherwise, it should be explained why existing cohorts are not used.
- Applicants need to define the standardized approach for sample collection, isolation and analysis methods and explain the tools they plan to use to measure nutritional status, dietary consumption, eating behavior, other lifestyle factors and cognitive decline as well as cognitive impairment through ageing in their proposals.

- Where relevant, investigations should employ existing biomarkers/surrogate outcomes that relate strongly to the risk of cognitive impairment. These include biomarkers related with the gut-brain axis, neuroendocrine signalling, and microbiota, especially those easily, affordable and feasible to obtain. Furthermore, other more sophisticated biomarkers derived from cerebrospinal fluid and image should be considered. The development of new biomarkers is not within the scope of the call.
- There may be opportunities to also use omics approaches, brain imaging, microbiota study linked, digital health data to get robust measures of diet, nutritional status, physical activity, sleep, social interaction, stress in well-characterised prospective cohort studies in adults and older people.
- The project should be consumer-centred: the involvement of the target population in the research is strongly encouraged at all stages of research design, implementation, analysis and dissemination. Research proposals are encouraged to also apply participatory methods, participatory agenda settings, informal settings, crowdsourcing data collection.
- Proposals should consider potential moderators of effects such as age, sex, gender and ethnic or other demographic features/differences in the respective research approaches.
- Where relevant, emerging model systems should be preferred to animal models. Research may make use animal models only for investigations that are impractical or unethical in humans and they must be justified. In this case, it is important to have mechanistic studies combined with observational research emphasising humans and it's needed a clarification on how the observations of animal models translate to humans (back and forth translation).
- The impact indicators shall be identified at the project proposal stage.
- Applicants are encouraged to consider the gender balance in the composition of the consortia and to balance the responsibilities between them.
- The proposed research shall not overlap with previous studies funded under the JPI HDHL and JPND calls or collaborations should be established.
- Early Career Scientists (Master students, PhD students and post-docs) are encouraged to participate in the consortium.
- Proposals that relate purely to the study of pathomechanisms are not eligible for funding in this call.

Please note that **additional conditions might apply at national level** (see Annex I).

## Expected Impact

The global burden of neurodegenerative diseases is predicted to triple by the year 2050<sup>2</sup>. Outputs from this call are expected to pilot test interventions based on the existing evidence in the literature or to upscale existing pilot interventions that will help to lower the risk of cognitive impairment manifestations related to a pathological brain ageing. This will include new insights on how lifestyle in general and in particular dietary choices, physical activity, sleep, social interaction, and stress may influence the trajectory of brain ageing that will underpin the development of new products, services and policies for middle-aged and older people. In the longer-run, improved brain ageing is expected to increase independence and to lower the individual, family, and social services of the burden and the expenses associated with age-related cognitive disorders. From a translational point, this will fill the gap between the scientific evidence on the protective role of healthy lifestyle factors and the current lack of systematic application in clinical, healthcare-related settings and active ageing policies.

## General conditions for application

The initial duration of the projects will be 36 months.

Proposals **must clearly demonstrate the potential health, economic, and/or policy impacts**, as well as **the added-value of transnational collaboration** i.e. sharing of resources (models, registries, diagnosis, etc.), harmonisation of data, sharing of specific know-how and/or innovative technologies.

**Proposals should follow the principles of Responsible Research and Innovation (RRI). All consortia should** demonstrate a commitment for investigating and addressing social, ethical, political, environmental or cultural dimensions of the proposed research. The proposal template further elaborates on this and how RRI dimensions can be approached.

Research supported by ERA4Health must respect fundamental ethical principles. Applicants have to describe any potential ethical aspects of the work to be carried out, and how the project will fulfil applicable requirements in institutional, national and European Union legislation (including the ethical standards and guidelines of Horizon 2020/Europe<sup>3</sup>).

The individual project partners of the joint applications should be complementary and the proposed work should contain novel, innovative and ambitious ideas with a high application potential to benefit of patients and citizens.

Furthermore, additional elements need to be considered in the application:

- If appropriate: the design of the study (sample collection, statistical power, interpretation, relevant models for hypothesis validation) must be well justified and should be part of the proposal.
- In case of an exploratory animal/ interventional study, a detailed description is required as part of the full proposal application form (requirements are included in the Guidelines for Pre-clinical and small-scale clinical studies up to phase 2). The review panel will

---

<sup>2</sup> Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 GBD 2019 Dementia Forecasting Collaborators, *Lancet Public Health* 2022; 7: e105–25 Published Online January 6, 2022 [https://doi.org/10.1016/S2468-2667\(21\)00249-8](https://doi.org/10.1016/S2468-2667(21)00249-8)

<sup>3</sup> [https://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics\\_en.htm](https://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics_en.htm)

scrutinize this information as part of the formal evaluation criteria (1-Excellence) of full proposals. Assistance for provision of the information on experimental design can be found in the general [ARRIVE guidelines](#)<sup>4</sup>.

## Participating countries and respective funding organisations

The following participating funding organisations have agreed to fund this call for transnational research projects:

| Countries | Funding organisations   | Acronym     | Contribution (€) |
|-----------|---|-------------|------------------|
| Austria   | Austrian Science Fund   | FWF         | 2 000 000        |
| Belgium   | Fund for Scientific Research-FNRS   | F.R.S.-FNRS | 300 000          |
| Belgium   | The Research Foundation - Flanders  | FWO         | 700 000          |
| Denmark   | Innovation Fund Denmark   | IFD         | 1 000 000        |
| Estonia   | The Estonian Research Council   | ETAG        | 150 000          |
| France    | French Research Funding Agency  | ANR         | 1 250 000        |
| Germany   | Federal Ministry for Education and Research (BMBF)/ represented by DLR Project Management Agency (DLR-PT) | BMBF/DLR    | 2 000 000        |
| Ireland   | Health Research Board   | HRB         | 500 000          |
| Israel    | Ministry of Health  | CSO-MOH     | 320 000          |
| Italy     | Ministry of Health  | IT MOH      | 1 500 000        |
| Italy     | Italian Ministry of Universities and Research   | MUR         | 1 000 000        |
| Latvia    | Latvian Council of Science  | LCS         | 450 000          |
| Lithuania | Research Council of Lithuania   | LMT         | 300 000          |
| Norway    | Research Council of Norway  | RCN         | 600 000          |
| Poland    | National Centre for Research and Development  | NCBR        | 1 250 000        |
| Romania   | Executive Agency for Higher Education, Research, Development and Innovation Funding                       | UEFISCID    | 1 000 000        |
| Slovakia  | Slovak Academy of Sciences  | SAS         | 240 000          |
| Spain     | Regional Ministry of Health and Consumer Affairs of Andalusia   | CSCJA       | 250 000          |

<sup>4</sup> <https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.1000412&type=printable>

|                 |  |         |               |
|-----------------|--|---------|---------------|
| Spain           | Institute of Health Carlos III   | ISCIII  | 400 000       |
| Spain           | Fundacion Para El Fomento En Asturias De La Investigacion Cientifica Aplicada Y Tecnologia | FICYT   | 250 000       |
| Switzerland     | The Swiss National Science Foundation  | SNSF    | 1 500 000     |
| Taiwan          | National Science and Technology Council  | NSTC    | 810 000       |
| The Netherlands | Dutch Research Council   | NWO     | 1 950 000     |
| Türkiye         | The scientific and technological research council of Türkiye                               | TUBITAK | 600 000 (TBC) |

Table 1: Participating funding organisations

Project partners will be funded by their relevant national/regional funding organisations. Eligible costs and funding rules vary between the respective funding organisations (see Annex I).

## Application

### ELIGIBILITY CRITERIA

Joint research proposals may be submitted by applicants belonging to one of the following categories (according to national/regional regulations certain categories may not be eligible for funding by a specific funding organisation, please see Annex I of the call text published on [ERA4Health.eu](http://ERA4Health.eu)):

- A. **Academia** – research teams working in public and private universities, other higher education institutions or research institutes.
- B. **Clinical/public health sector** – research teams working in hospitals/public health and/or other health care settings and health organisations, including primary health care.
- C. **Enterprises** – companies dedicated to communication, involved in health research and innovation.
- D. **Operational stakeholders** – e.g., patient advocacy organisations, municipalities and local governments, local/national NGO's. In line with the concept of Responsible Research and Innovation (RRI), operational stakeholders should provide useful knowledge to the consortium and ensure the consortium's research is useful and translatable to their (or other) organizational contexts. Furthermore, they could contribute by influencing decision making and creating changes within their organisations. Operational stakeholders should be engaged throughout the whole duration of the research project, from the conception of the study to dissemination.

Consortia submitting applications to this call are strongly encouraged to include partners from all the different categories (A, B, C, and D) in line with the crosscutting/multidisciplinary nature of the call, whose aim is to include partners along the entire supply chain value.

Only transnational projects will be funded.

### Size of the consortium

The number of participants and their research contribution should be appropriate for the aims of the transnational research project and be reasonably balanced in terms of international participation. Each

transnational collaborative project should represent the critical mass to achieve ambitious scientific goals and should clearly demonstrate an added value from working together.

Only transnational projects will be funded. The following conditions apply to the composition of a consortium:

A minimum of 3 (three) eligible and a maximum of 5 (five) eligible partners from at least 3 (three) different countries participating in the call.

- The maximum number of eligible partners can be increased up to 6 (six) or 7 (seven) if they include 1 (one) or 2 (two) partners from the following participating countries: Estonia, Latvia, Lithuania, Romania, Slovakia
- No more than 2 (two) eligible partners from the same country participating in the call will be accepted within one consortium.
- A maximum of 2 (two) collaborators per consortium. Collaborators are self-funded partners: i.e., partners that do not request funds to any of the participating funding organisations (i.e., partners from non-funding countries or partners which are not fundable according to national/regional regulations of the participating funding organisations).

The following conditions apply for collaborators:

- Clear added value for the research project. This should be demonstrated in the proposal.
- Secure own funding for participation with clear evidence in the proposal that this is already in place.
- A letter of commitment of the collaborator(s) needs to be included as an annex to the pre-and full proposal.
- A collaborator cannot be work package leader.

Each principal investigator can submit either **one proposal as project coordinator or up to two proposals as simple partner** (i.e., the coordinator of a proposal cannot be partner in another proposal).

| Number of partners requesting funding (eligible partners) | 3-5            | 6          | 7          |
|---|----------------|------------|------------|
| Partners from underrepresented countries <sup>5</sup>     | No constraints | At least 1 | At least 2 |
| Maximum number of collaborators                           | 2              | 2          | 2          |

Table 2: Possible composition of a research consortium

Each project consortium must nominate a **project coordinator** from the participating principal investigators (NOT a collaborator). The project coordinator will represent the consortium externally and will act as contact person for the Joint Call Secretariat (JCS) and will be responsible during the

entire process for the internal scientific management such as controlling, overseeing IPR issues, reporting, and contact with the JCS.

Each principal investigator can submit only **one proposal as project coordinator or up to two proposals as mere partner** (i.e. the coordinator of a proposal cannot be partner in another proposal) Please note that this rule may be subject to national/regional regulations. Applicants are consequently strongly encouraged to contact their national/regional contact points to check their national/regional eligibility rules before submission (see Annex I).

**A partner search tool**, available on ERA4Health website<sup>6</sup>, can be used to offer your support or look for a partner.

#### Financial and legal modalities

Project partners will be funded by their relevant national/regional funding organisation. Therefore, eligible costs, funding rules and the type of studies allowed will vary between the different funding organisations (see Annex I). Due to these differences, it is recommended that each project partner defines its own budget in accordance with the funding rules of its own country/region.

For information on the specific funding rules and eligibility criteria of the national/regional funding organization

- Carefully read Annex I and the national/regional announcements of the call
- In addition, applicants are strongly advised to reach out to their relevant funding organisation contact person before applying; please, also note that for some countries/regions it might be mandatory.

#### Submission of joint proposals

The submission and evaluation procedure will be in two-steps for joint applications. The second step of the evaluation process will include a rebuttal stage. For both steps, proposals (in English) shall be prepared by the consortium partners following the ERA4Health template and must be submitted via the electronic submission system tool Pt-outline (link on [ERA4Health.eu](https://era4health.eu)) by the project coordinator. The two-step application process will have the following timeline:

|                                    |  |
|------------------------------------|--|
| <b>3 November, 2023</b>            | <b>Publication of NutriBrain call</b>  |
| <b>15 January, 2024, 16h00 CET</b> | <b>Deadline for pre-proposal submission</b>  |
| 27 March, 2024                     | Communication of the results of the pre-proposal assessment (invitation for full proposal) |
| <b>27 May, 2024, 16h00 CEST</b>    | <b>Deadline for full proposal submission</b>   |
| <b>12 – 23 August, 2024</b>        | <b>Rebuttal stage</b>  |
| Mid-October 2024                   | Communication of the funding decisions to the applicants                                   |
| <b>December 2024 – May 2025</b>    | <b>Expected project start</b> (subject to national procedures)                             |

Table 1: Timeline application process

<sup>6</sup> <https://era4health.eu/partner-search/>

The pre-proposal template will be available on the ERA4Health website.

An application template for the full proposal stage will be sent to the project coordinator by the JCS with the invitation to submit a full proposal.

Pre-proposals or full proposals submitted without using the relevant template will be declared non-eligible.

If applicable, a proposal should be submitted together with a legal/ethical approval document according to the concerned country's/region's regulations.

For applicants from specific countries/regions it might be mandatory to submit the additional national/regional proposal and/or other information, in some cases before the deadline of this call, directly to the national/regional funding organisations. Therefore, applicants are strongly advised to check their funding organisations specific regulations. See Annex I for more details.

The Call Steering Committee will take all lawful steps to ensure confidentiality of the information and documents obtained during the evaluation and selection procedure of the joint call.

#### Further information

For additional information, please contact the JCS, or your national/regional funding organisation Contact Person (see Annex I).

## Evaluation and decision

### Eligibility check and evaluation procedure

#### Eligibility check and evaluation of pre-proposals (first step)

The Joint Call Secretariat (JCS) will check all proposals to ensure that they meet all the eligibility requirements of the call (i.e., date of submission; number and category of participating countries; application entirely written in English; appropriate limits on length). In parallel, the JCS will forward the proposals to the national/regional funding organisations, which will perform a check for compliance with national/regional regulations.

Each proposal passing the eligibility check (JCS and country/region) will be allocated to three reviewers avoiding any conflicts of interest. The reviewers will perform the assessment of the pre-proposals in accordance with the evaluation criteria described below and complete a written evaluation form with scores and comments for each evaluation criterion. Starting from the scores assigned by the three reviewers, the JCS calculates the total score for each proposal averaging the scores assigned to each criterion by the three reviewers and then summing up the averages. This final score will be used to rank all pre-proposals.

The Call Steering Committee members (CSC, composed of one representative of each funding organisation participating to the call) will meet to decide which proposals will be invited to submit a full proposal based on the ranking list prepared by the JCS and ensuring a reasonable balance of requested and available national/regional budgets. Pre-proposals which do not pass this selection phase, will not be considered for the full proposal stage.

The applicants will receive the outcome of the evaluation, that will include advice on their RRI approach where necessary.

### Eligibility check and evaluation of full proposals (second step)

The JCS will check the submitted full proposals to ensure that they meet the call's eligibility criteria and that the proposed research programme described in the respective pre-proposal have not changed substantially, before sending them to the reviewers. Any substantial change between pre- and full proposals, e.g., concerning the composition of the consortium, the objectives of the project or the requested budget must be communicated to the JCS and to the national/regional funding organisations involved. In exceptional cases, these changes may be admitted if detailed justification is provided and if they are accepted by CSC.

Each full proposal will be allocated to three reviewers avoiding any conflicts of interest. The reviewers will perform the assessment of the full proposal in accordance with the evaluation criteria described below and complete a written evaluation form with scores and comments for each criterion.

Immediately after this step and before the Peer Review Panel (PRP) members meet to discuss each full proposal in a PRP meeting, each coordinator will receive the written evaluation form and will be able to respond to the arguments and evaluations of the reviewers (see section "Rebuttal").

During a PRP meeting, the reviewers will discuss all proposals and produce a final ranked list of proposals dividing them in three categories:

- A: highly recommended for funding
- B: recommended for funding if there is funding available
- C: not recommended for funding

### Evaluation Criteria

#### 1. Excellence

The following aspects will be taken into account, to the extent that the proposed work corresponds to the topic description in the Call text:

- a. Scientific quality of the proposal:
  - Relevance of the research question
  - Clarity and relevance of the objectives
  - Credibility and clarity of the proposed approach and methodology, including power calculations, randomisation, blinding and bias, target group(s) studied, as well as approach to RRI and appropriate consideration of gender dimension in the research
  - Expected progress beyond the state-of-the-art, clearly demonstrating an innovation potential
  - Quality of the project consortium: international competitiveness of participants in the field(s), previous work and specific expertise of the participants, complementarity of the participants, benefit of the transnational collaboration.
- b. Novelty and ambition (including translatability of the proposed research to human health).

#### 2. Impact

The following aspects will be taken into account:

- a. Unmet public and societal need and potential impact of the expected research results for future clinical, public health, and/or other socio-economic health relevant applications including patients' needs and/or for industry (i.e., product development).
- b. Added value of transnational collaboration and potential for fostering international network: gathering a critical mass of patients, sharing of resources (biological material, models, databases, etc.), harmonization of data, sharing of specific know-how and/or innovative technologies, etc.
- c. Projects with high potential of applicability at short/medium term: expected time for market and transfer to patient towards clinical and public health applications, pharmaceutical/health device applications, other industrial applications including market and end user's scenario, quality of dissemination, exploitation, and business plan (when appropriate/applicable).
- d. Participation/engagement with end-users such as patients, industry, clinicians (when appropriate/applicable).
- e. Effectiveness of the proposed measures to exploit and disseminate the project results (including management of intellectual property rights), to communicate the project results in a tailored manner to the different audiences (e.g., policy makers, industry, patients), and to manage research data where relevant.

*Please note that sub-criterion 2e will be evaluated at the full proposal evaluation stage.*

### **3. Quality and efficiency of the implementation**

The following aspects will be taken into account:

- a. Feasibility for the duration of the proposal and likelihood of success in achieving the objectives of the proposed research.
- b. Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks, resources and timeframe.
- c. Use of existing biobanks and existing cohorts (when appropriate/applicable).
- d. Adequacy of the budget: appropriate distribution of resources in relation to project activities, partner's responsibilities, and time frame.
- e. Appropriateness of the management structures and procedures, including risk, innovation management and RRI, and ethical considerations.
- f. Sustainability of the research capacities initiated by the project (e.g., FAIR data management, Open Science practices). Quality of the Intellectual Property management.

*Please note that sub-criterion 3d, 3e and 3f will be evaluated at the full proposal evaluation stage.*

**Proposals out of the scope of the call topic and objectives will not be funded, independently of their scientific quality.**

#### Scoring system

Evaluation scores will be awarded for the three main criteria. Each criterion will be scored out of five. The weight of each of the three main criteria is equal.

**0 = Failure.** The proposal fails to address the criterion or cannot be assessed due to missing or incomplete information.

**1 = Poor.** The criterion is inadequately addressed, or there are serious inherent weaknesses.

**2 = Fair.** The proposal broadly addresses the criterion, but there are significant weaknesses.

**3 = Good.** The proposal addresses the criterion well, but a number of shortcomings are present.

**4 = Very Good.** The proposal addresses the criterion very well, but a small number of shortcomings are present.

**5 = Excellent.** The proposal successfully addresses all relevant aspects of the criterion. Any shortcomings are minor.

Only integer values are accepted.

**Funding thresholds: a full proposal will be considered fundable if the score for each individual criterion is at least 3 points and the overall score at least 10 points.**

### Rebuttal stage

Before the PRP members meet to discuss the full proposals in a PRP meeting, each coordinator is provided with the evaluation form produced by the reviewers. This stage allows applicants to comment on factual errors or misunderstandings that may have occurred in the review process and to reply to reviewers' comments. However, issues not related to reviewers' comments cannot be addressed and the work plan cannot be modified at this stage.

The applicants will have 12 days for this optional response to the reviewers' comments.

### PRP meeting

The JCS will give the PRP members access to full proposals, reviews and rebuttals, avoiding any conflicts of interest. The PRP will meet to discuss each proposal and, after consideration of the evaluation criteria, the reviews, rebuttal letters, and discussions, the PRP will assign final scores and rank the proposals. The final summary review report prepared by the PRP members will be sent to the respective project coordinators.

### Ethical clearance

After the PRP meeting, ethical experts will remotely check the full proposals, which are recommended for funding by the PRP and selected for funding by the CSC, for alignment with ethical norms and regulations. If necessary, tasks that need to be performed and documents that need to be submitted by the consortium will be listed. The Ethics experts may put forward additional conditions that need to be fulfilled by applicants during the project implementation. Only those proposals approved by both the scientific evaluation and ethical assessment will be funded.

### Decision

A final decision, based on the ranking list established by the PRP, available funding and the ethical clearance, will be taken by the national/regional funding organisations.

Project coordinators having submitted an eligible proposal will be informed about the funding recommendation regarding their proposal by the JCS. The projects coordinators are responsible to communicate this information to their project partners.

### Redress procedure

Applicants can appeal against the evaluation outcome if they suspect a breach in the application of the evaluation and selection procedures. This redress procedure only covers the procedural aspects of the evaluation and/or eligibility checks, including the national eligibility checks. The redress will not call into question the scientific or technical judgement of appropriately qualified experts.

In this case they shall submit their appeal to the JCS via email ([nutribrain@mur.gov.it](mailto:nutribrain@mur.gov.it)), up to 7 calendar days after the date of dispatch of the evaluation outcome email by the call secretariat at the end of each stage (first or second step).

The proposal outcome email containing the results of the evaluation will give information on the appeals procedure, which is described below.

### Admissibility of appeals

For an appeal to be admissible the following conditions must be met:

- The appeal must be submitted by the coordinator of the proposal to which the appeal relates
- Only one appeal per proposal will be considered
- The appeal must be submitted via email within the 7 calendar days deadline. The appeal must contain the following minimum information:
  - The name of the call for proposals;
  - The proposal acronym;
  - The title of the proposal;
  - A description of the alleged shortcomings of the evaluation procedure.

The appeal must demonstrate a procedural irregularity, factual error, manifest error of assessment, misuse of powers, or a conflict of interests. Appeals that do not meet the above conditions, or do not deal with the evaluation of a specific proposal or express mere disagreement with the result or the reasoning of the evaluation might be judged as not suitable for redress.

### Procedure

Upon receipt of an appeal, an acknowledgement of receipt will be sent by the call secretariat within 7 calendar days. The acknowledgement shall report the redress process and the anticipated date by which a decision on the appeal will be communicated to the appellant.

All appeals received by the 7 calendar days deadline will be processed together and the decision will be communicated to the appellant within 7 calendar days from the deadline for submitting the appeals.

## Responsibilities, Reporting requirements and Dissemination

### Consortium Agreement

It will be the responsibility of the project coordinator to draw up a Consortium Agreement (CA) suitable to the project partners in order to manage the delivery of the project activities, finances, intellectual property rights (IPR) and to avoid disputes which might be detrimental to the completion of the project. The CA should also include a section dedicated to the privacy and sensitive data management. The project consortium is strongly encouraged to sign this CA before the official project start date, and in any case the CA should be signed in the first 6 months of the project. Please note that national regulations may apply concerning the requirement for a CA (e.g. certain funding organisations may need the signed CA to release some funds). Further instructions will be provided by the JCS to the coordinators of the projects selected for funding.

### Open Science

Importantly, all funding recipients must ensure that all outcomes (publications, etc.) of transnational ERA4Health-funded projects are published with Open Access. All research projects funded by ERA4Health are eligible to publish on **Open Research Europe (ORE)**, the [Platform of the EC](#)<sup>7</sup> at no cost.

The new research data resulting from the project should be treated according to the [FAIR](#)<sup>8</sup> principles, and deposited and shared, according to the national rules of the countries involved. To make research data findable, accessible, interoperable and re-usable (FAIR), a Data Management strategy for the proposed full projects is mandatory in the second evaluation stage. Projects selected to receive funding in the current call, will be requested to present a more detailed Data Management Plan (DMP) before month 6 from the official start of the project and an update of the DMP will be asked at the end of the projects.

### Progress report

The project coordinator is required to submit an annual scientific progress report on behalf of the consortium to the JCS in March of each year, detailing how the project is progressing in relation to planned objectives. Furthermore, a final scientific report must be sent to the JCS within a period of two months after the project has ended. In addition to the reports, information related to some indicators related to the project may be collected on a platform/survey.

National funding organisations may also request financial and/or scientific annual progress reports and/or a final report on the project from the partners from their respective country.

In addition, the coordinators of each consortium may be asked to participate in a kick-off meeting and present two progress updates, one mid-term and one final status symposium. An appropriate travel budget should be included and justified in the financial plan for the proposal. In case some of the events are organised as an online conference, all partners of the consortia will be encouraged to participate.

### Communication

The project coordinator will represent the consortium externally and will be responsible for all communication with the relevant ERA4Health bodies. The coordinator must promptly inform the JCS in case of ANY significant changes in the work plan or the consortium's composition. The JCS will inform the relevant funding organisations, who will decide upon the proper action to be taken.

Project coordinators, upon notification, are required to deliver an abstract of their project suitable for communication and dissemination purposes.

For the effective contribution of the project to the objectives of the ERA4Health, the project coordinator should be available to participate in meetings/workshops with the aim of:

- exchanging project results;
- developing a joint strategy to coordinate and facilitate integration of the planned activities of ERA4Health;
- communicating results across ERA4Health.

---

<sup>7</sup><https://open-research-europe.ec.europa.eu/>

<sup>8</sup> <https://www.nature.com/articles/sdata201618>

Importantly, all funding recipients must ensure that all outcomes (publications, etc.) of transnational ERA4Health funded projects include proper acknowledgement of the ERA4Health partnership and the respective funding partner organisations.

*“This project received funding from [name of funding organisations, or an acknowledgment as requested by your national/regional funding organisations] under the umbrella of the Partnership Fostering a European Research Area for Health (ERA4Health) (GA N° 101095426 of the EU Horizon Europe Research and Innovation Programme).”*

## Support for Early Career Scientists

All project coordinators and principal investigators (PI) are asked to encourage the Early Career Scientists (ECS) that will be involved in the research projects to actively engage in the upcoming ERA4Health Early Career Network (ECN). The aim of the ECN is to foster the interaction, capacity and growth of Early Career Scientists (ECS) involved in ERA4Health-funded projects. Different networking, training and capacity building activities dedicated to ECS will be organised and implemented during the runtime of the projects.

To facilitate participation of the ECS in the ECN, the coordinators and PIs should (I) include travel costs for the project’s ECS dedicated to the ECN activities in the proposal and (II) allow the ECS to dedicate a small amount of their working time to the ECN. In addition, the research consortia are invited to include training activities for Early Career Scientists into their proposals. Examples of training activities are mobility and lab visits of ECS between partners of the consortium or implementation of summer school(s).

## Confidentiality

The ERA4Health JCS takes all reasonable steps to ensure that information provided in the application is treated confidential.

The proposals will be handled confidentially by the JCS and by the national/regional funding organisations. In selecting the international experts for the PRP, the JCS shall endeavour to avoid any possible conflicts of interest (CoI).

Each expert will have to sign a declaration of confidentiality and absence of conflict of interest. In case of a CoI the reviewer will be withdrawn from evaluating the respective proposal. The handling of conflicts of interest is established at each PRP and JCS meeting and is noted in the minutes.

## General Data Protection Regulation

The following Data Privacy Notice applies:

By submitting an application, the applicants consent to the use, processing and retention of their personal data<sup>9</sup>, in accordance with article 6.1 (e) and (c) of the General Data Protection Regulation (GDPR) (2016/679) and for the purposes of:

- processing and evaluating the application where processing shall be lawful only if and to the extent that processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller,
- administering any subsequent funding award,
- managing the funding organisations relationship with them,
- analysing and evaluating the call,
- providing aggregate data to national and European surveys and analyses on the funded projects,
- and complying with audits that may be initiated by the funding organisations and the European Commission (or its agencies).

The members of the CSC may share applicant's data with third parties (some of which may be based outside the European Economic Area) in relation to the above activities including evaluators, auditors and the European Commission (or its agencies).

The members of the CSC may link the data that funding recipients provide in the application with national, bibliographic or external research funding data which are available through public subscription-based databases (e.g. Scopus, Web of Science, etc.) or other national / open datasets.

---

<sup>9</sup> Last name, first name of the researchers, date of birth, professional contact information, degree(s), position (current and previous), fields of activity, place of work, organisation, address(es), curriculum vitae, ORCID number, name and reference of projects, pre-proposals, project proposals (scientific document, administrative and financial appendix).

# ERA4Health Responsible Research and Innovation (RRI) Guidelines


## What is RRI and why do we need it?

Health research and innovation is crucial for maintaining and improving European public health. In this context, it is easy to acknowledge that science is not separate from society but part of it, which confers an important social responsibility on science. It is important, therefore, that funders, researchers and other key groups involved in the development of science, technology and innovation think about: (i) the potential directions of research being taken; (ii) who might benefit from new research and inventions and who might not; and (iii) how consideration of the potential social, environmental and ethical issues can be considered throughout the science and innovation process. Responsible research and innovation (RRI) is not about adjudicating what is 'good' or 'bad', 'positive' or 'negative', or 'responsible' or 'irresponsible'. Instead, RRI offers techniques, tools and frameworks to think about questions of social responsibility and ensure scientists, funders and technologists don't lose sight of the context in which they do science, technology and innovation.

RRI is closely related to other cross-cutting issues, and actions can be taken that address both RRI and other important values, such as public/user engagement, open science or ethical assessments.

## What is ERA4Health's approach to RRI?

ERA4Health's approach to RRI is focused on improving the quality of research and innovation by keeping the broader context of your work visible. It encourages you to embed methodologies and processes to consider four important dimensions related to research and innovation:



**Anticipation.** What might the future desirable and undesirable effects of your work be? Who will benefit from it, and who might not? Can decisions be made now to encourage the good, while minimising the bad effects? This isn't about exhaustive prediction but about building a sense of preparedness for the future.



**Inclusion.** Whose voices and knowledge are shaping your research project? In health research, much evidence shows that patient organisations, health care users and health professionals (amongst others) can improve the quality of innovation. Inclusion is about creating opportunities for two-way exchange of information, co-design or knowledge co-production to draw important outside voices into the research process.



**Reflection.** Are there opportunities for you and your team to pause and take stock' about what you're doing? Would everyone agree with your goals and the decisions you've taken so far? Reflection is about making sure there is space and time to collectively ask hard questions about a project's foundations.

**Responsiveness.** What are the key decision points in your project? Are there opportunities to change course, if you need to? The final dimension is a reminder that the work you do under the label of RRI needs to shape the design, governance or use of your research or innovation.



**In sum RRI provides a framework to ask how research and innovation should be carried out in order to ensure that we achieve the societal goals of research and innovation in an open and inclusive way.** ERA4Health believes that the RRI methodology improves the quality of research proposals and projects, and substantively engaging with this framework will therefore be rewarded in the proposal evaluation process.

#### How should you include RRI in your project?

Experience with past funding programmes shows that these four dimensions – anticipation, inclusion, reflection and responsiveness – provide a useful heuristic to think about social responsibility across a range of domains. However, the diversity of health science and the range of local contexts engaged within ERA4Health means that there cannot be a one size fits all approach. The specific approach to RRI must be tailored to the actual social, environmental and ethical issues raised by a project’s research and innovation activities.

This means that **the commitment** to RRI is clear and fixed in the programme, but there is an openness about the issues addressed and the specific ways to practise responsibility – these must be adapted to each project. In general, your approach to RRI should be proportionate to your proposal – disruptive, ground-breaking or high-TRL (Technology Readiness Level) work is likely to require a more substantive engagement with RRI. If the research is exploratory then RRI components can also be exploratory – teasing out the potential visions, goals and end uses of a project. Overall, the goal is to demonstrate that you have engaged and seriously considered the tensions and meaningful societal benefits associated with health research and innovation.

**The text below therefore provides overall ideas and advice but cannot give a recipe that all potential applicants may use.** However, the following four points will provide a good foundation as to how develop your approach to RRI in your proposal:

1. Treat **RRI as an integrated part of the project** involving as many project members as possible. Do not think of RRI as distinct from the science but as central to it. It is a process that will increase the likelihood of delivering applications with real utility, fair accessibility and concrete value for citizens.
2. It is important to develop a **shared understanding of the project’s RRI aspects** as early as possible, and for the work plan to be specific to the project. Avoid writing generic, boiler-plate text. By ‘RRI aspects’ we mean implications or characteristics of your research that touch upon societal, ethical and environmental values.
3. **Develop the scientific and RRI components in tandem.** This means you will need to have conversations about the goals, uncertainties and assumptions associated with the scientific ideas. It is important to continue these conversations if the project is funded.

4. **Make sure you adequately resource RRI.** It takes time, effort, expertise and money to do RRI well. While there is no one approach to operationalising RRI within a project, ideally RRI needs to be coordinated and should have a lead.

But what should you actually do?

Starting points to help you identify the most relevant dimensions for your project.

The following questions will direct you to different RRI perspectives applicable for health research and innovation projects. Many of these perspectives can be explored in a structured way with a range of methodologies (for additional resources, see box below).

**Please be aware that these options neither represent a complete list of examples, nor the mandated approaches to RRI by ERA4Health.**

**1. Who will benefit from your project, who will not, and who may experience new risks? Are those answers acceptable to you?**

- a. Does your project address a specific health-related or societal problem or need?
- b. Will your innovation be affordable and accessible? If not, is that a problem?
- c. Does your framing of the problem fit with other people's understanding of it? Can you access these alternative framings?
- d. How does your approach to the health challenge compare to others approaches?
- e. What is the most appropriate form of intellectual property (IP) for your project goals and affordability aspirations? Do classical IP strategies deliver the broadest benefit? Can new strategies (e.g. Open Material Transfer Agreements) be adopted at certain points of the research process?
- f. How could commercial or non-commercial organisations benefit from your research?
- g. Are there foreseeable risks that you can mitigate now? For instance, what are the potential risks of data being released? How can you take care to ensure these data are interpreted appropriately?

**2. Have you identified and involved relevant stakeholders and have you considered public engagement activities?** Are there opportunities for stakeholders and the public to contribute to your work? Stakeholders are people or organisations with a vested interest in the project (both positive and negative), who may also contribute knowledge to it. They could be patients, minorities and marginalised groups, health system users, special interest groups, health professionals, companies, nonprofits, or advocacy organisations. A number of different considerations for stakeholder engagement are important:

- a. **Think about the methodology you will use.** For instance, 'co-design' and 'knowledge co-production' methodologies are good at generating trust and allowing stakeholders, including the public, to contribute their knowledge to the problem your project is trying to address.

- b. **Think also about the appropriate timing** of different stakeholders' inclusion: certain kinds of knowledge may be more useful early on, whereas other knowledge may be useful later.
- c. It will likely be valuable (but not obligatory) to **include expertise beyond the medical and health sciences** – such as lawyers, social scientists or philosophers – to provide anticipatory and reflective methodologies or to address key challenges. Approach them early in your project design.
- d. Think about **how best to formalise and include stakeholder knowledge** in your project. Are they best placed as scientific collaborators, as members of an advisory board, or as consultants to deliver only specific tasks? Check if your approach is in line with the national/regional funding rules before designing your proposal.

**3. Have you created good deliberative spaces** for your project team, partners and aforementioned stakeholders, including the public, to anticipate and reflect on the broader social, political, ethical or environmental context of your research? If not, RRI experts in Science and Technology Studies, medical sociology, bioethics and science communication may be able to help you with this in project design and implementation. A number of different approaches are possible, e.g.:

- a. Focusing on your day-to-day research work (“philosopher in the lab approach”).
- b. Using foresight and critical futures methodologies.
- c. Utilising a diverse advisory board.
- d. Trans-disciplinary reflection at consortium meetings.
- e. Using stage-gate approaches where explicit decisions about technological choices are taken.

**4. Have you reflected on/considered adapting your choice of research methods** regarding, for example:

- a. Ethical issues in the project (including ethical considerations in the design of participatory science and possibly broader than the “ethics self-assessment”)?
- b. The use of data in your project – where does it come from, how will it be used and where will it go? How will ethical use be ensured?
- c. In vivo/in vitro experiments and need for use of animals in experiments?
- d. Use of new approaches such as “Safe(r) by Design”?
- e. Your ability to increase the likelihood of translation by outlining e.g. strategies of scientific rigour, and strategies to reduce bias, inclusion of sex/gender as a biological variable in study design?
- f. Open Science (such as open data, open code, open protocol or other low barrier data sharing practices) and other publication practices (including report all results, also negative or so-called null results)?
- g. And are there ways that your project can advance common practices on these issues?

**5. Have you engaged with important aspects of your research environment** such as:

- a. gender, ethnicity and intersectional equality, diversity and inclusivity?
  - b. career progression and precarity?
  - c. equity between partners in your research consortium?
- 6. Have you shown how the project (and product) satisfy requirements for **patient and production safety** and efficiency? Will there be clear benefits for the patient by, for example by:**
- a. listening to/satisfying user needs and safety concerns, or involving them in design;
  - b. involving regulatory affairs professionals (toxicity tests, etc.),
  - c. communicating with regulatory entities as early as possible (the Food and Drug Administration (FDA) or the European Medicines Agency (pharmaceuticals and medical devices), etc.
- 7. Have you considered and evaluated **environmental impacts and sustainable solutions**, in line with the **Do No Significant Harm principle**<sup>10</sup>, by including, for example:**
- a. lifecycle analysis (LCA)?
  - b. ecotoxicology studies?
  - c. safer- sustainable-, or recyclable-by-design methodologies?

#### How does ERA4Health support and evaluate RRI?

Health research and innovation happens in many different locations (e.g. universities, hospitals, care homes, companies, policy organisations), involves different stages of research (i.e. across the TRL spectrum) and different research cultures. Responsibility for innovation must be shared, and RRI therefore requires a multi-level approach.

ERA4Health is taking a systemic approach to RRI, considering it in the development of the annual work programme and the resulting funding calls. These guidelines were developed in collaboration with members of the ERA4Health community, and will be updated on a rolling basis. The programme's capacity building activities will also facilitate a dialogue among stakeholders in health research about RRI and ethical issues.

At the level of research projects, **ERA4Health requires that all proposers explain how their projects demonstrate a commitment to investigating and addressing the social, environmental, ethical, political or cultural dimensions of the proposed research.** Integration of RRI should lead to an improved understanding and awareness of the possible benefits, risks, and uncertainties of health science across a broad cross-section of society. This may include (but is not limited to) any of the approaches described in the above section.

**In the (pre-)proposal templates**, three sections/points refer to RRI and ethics considerations and leave space for you to explain your approaches:

---

<sup>10</sup> For more information on this principle see point 15 in Horizon Europe's Programme Guide, page 39: [https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide\\_horizon\\_en.pdf](https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf)

- General RRI aspects
- Involvement of stakeholders and the public
- Ethical considerations (in your ethics self-assessment)

**RRI components will be given advice on/evaluated by experts as integral components within the scope of all evaluation criteria (Excellence, Impact, and Implementation).** RRI does not detract from the overall scoring but contributes to it: Proposals that explicitly aim to advance processes of anticipation, reflection, inclusion and responsiveness by developing new analyses or methodologies will be rewarded in the review process and the scores will be adjusted accordingly. In pre-proposals: The research consortia will receive advice on the RRI dimension from their proposal via written comments from an RRI Adviser that will be shared with the reviewers. In full proposals: RRI Advisers will comment on proposals before the Per Review Panel (PRP) meeting and be invited to give additional advice on RRI and support the discussions during the PRP meeting. The kinds of questions the RRI Advisers/reviewers will ask regarding RRI are:

#### Relating to Excellence

- Is the RRI approach proportionate to the content of the scientific proposal?
- Does RRI extend across the lifespan of the project? (e.g. as a sub-project, an advisory board or to be considered in annual meetings)
- Are there clear deliverables associated with the RRI work, with ambitions to contribute to RRI scholarship and/or new knowledge of the social, political, ethical or environmental dimensions of health science?

#### Relating to Impact

- Are there clear opportunities for the RRI work to shape the project's scientific trajectories?
- Does the RRI work help align the project's research better to the needs and values of society?

#### Relating to Implementation

- Is there appropriate RRI expertise in the project?
- Is RRI work adequately resourced? Is it clear how the objectives will be achieved?
- Is it clear how the work is organised? (e.g. as a work package, a cross-cutting issue, outsourced etc.)
- Is it clear who is doing the work and what they will do?

### **WEB RESOURCES FOR INCLUDING RRI IN YOUR PROJECT:**

[www.rri-tools.eu](http://www.rri-tools.eu) provide numerous resources for practical RRI.

<https://thinkingtool.eu/>: The Societal Readiness Thinking Tool guides you through the steps of including RRI in a project.

The Centre for Digital Life Norway [has also compiled a range of resources](#) that may help develop your approach.

Tools for public engagement: <https://www.publicengagement.ac.uk/resources> and <http://actioncatalogue.eu/>

Further examples specific to health science and innovation will in the future be provided on the RRI webpage of ERA4Health (coming).

ERA4HEALTH's approach to RRI builds on previous frameworks published by the UK's [EPSRC](#), the Research Council of Norway, the [European Commission](#) and funding programmes such as [M-ERA.NET](#), [ERA CoBioTech](#) and [EuroNanoMed3](#).

## ANNEX I National/Regional Annexes

|  |  |
|--|--|
| <b>Country</b>   | <b>Austria</b>   |
| <b>Funding organisation</b>  | <b>FWF Austrian Science Fund</b><br><a href="http://www.fwf.ac.at">www.fwf.ac.at</a>   |
| <b>National contact person</b>   | Markus Kubicek<br>Tel.: +43 1 505 67 40 - 8202<br>E-Mail: <a href="mailto:markus.kubicek@fwf.ac.at">markus.kubicek@fwf.ac.at</a><br><br>Stefanie Schagginger<br>Tel.: +43 1 505 67 40 - 8213<br>E-Mail: <a href="mailto:stefanie.schagginger@fwf.ac.at">stefanie.schagginger@fwf.ac.at</a>   |
| <b>Funding commitment</b>  | € 2.000.000  |
| <b>Anticipated number of fundable proposals</b>                        | The FWF anticipates funding of 5 projects, given an average amount of funding per partner of approx. 400.000.  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | The FWF generally does not have any minimum or maximum limits but, given the limited nature of the financial commitment of the FWF to this Call (see above), we do expect Austrian participations not to exceed the average range of an FWF stand-alone Project (typically € 300.000 to €450.000 ).  |
| <b>Eligibility of partners</b>   | Individual researcher or teams of researchers, working in any kind of non-profit organisation: e.g. University, University hospital, Non-university research institute.<br>Please refer also to the general FWF Funding Guidelines: <a href="http://www.fwf.ac.at/application-guidelines-principal-investigator-project-profi-mode">Application guidelines Principal Investigator Project (PROFI mode) (fwf.ac.at)</a><br>also available on: <a href="http://www.fwf.ac.at/joint-projects-era-nets">Joint Projects / ERA-Nets (fwf.ac.at)</a>  |
| <b>Eligibility of costs, types and their caps</b>                      | The current FWF salary scale ( <a href="http://www.fwf.ac.at/personnel-costs">Personnel costs (fwf.ac.at)</a> ) indicates the salaries that may be requested. The FWF grants an annual salary adjustment to compensate for inflation; this is applied automatically to all contracts of employment in Principal Investigator projects that are valid when the adjustment takes effect.<br>For scientists funded by the FWF, the funding is limited to “project-specific costs”, i.e. personnel and non-personnel costs that are essential to carry out the project and that go beyond the resources made available from the research institution’s infrastructure, according to the general FWF Funding Guidelines published at <a href="http://www.fwf.ac.at/application-guidelines-principal-investigator-project-profi-mode">Application guidelines Principal Investigator Project (PROFI mode) (fwf.ac.at)</a><br>The FWF does not finance infrastructure or basic equipment at research institutions. Overheads may not be requested. Subcontracts must be well justified, i.e. must represent the only or the most economical way to have the work performed, please contact the FWF directly for clarification of individual cases. |
| <b>Submission of the proposal at the national level</b>                | In addition to the application at the ERA4Health level, administrative data (in accordance with the FWF guidelines for Principal Investigator Projects) must be submitted online to the FWF at <a href="https://elane.fwf.ac.at/">https://elane.fwf.ac.at/</a>   |

|  |  |
|--|--|
|  | <p>This is required already at the pre-proposal stage via the programme category “PIK – International Projects preproposal” deadline January 16, 2024, 15:00 CET (local time in Brussels). For the full proposal stage applicants must choose the programme category “PIN– International Projects” (Deadline May 28, 2024, 15:00 CEST (local time in Brussels). <b>Both steps are mandatory.</b></p> <p>All proposals must be submitted using the elane online portal. Project funding is administered through the research institution (PROFI); for this reason, the submission must be approved in the application portal both by the applicant and by the respective research institution.</p> <p>Please note that the number of ongoing/approved projects in which one researcher can serve as principal investigator is limited to three in the Stand-Alone Projects Programme, International Programmes, Clinical Research and Arts-Based Research Programmes. Information on the limit of the number of ongoing/approved projects and the limit of applications that can be submitted can be found at <a href="http://project_number_limit.pdf(fwf.ac.at)"><u>project_number_limit.pdf (fwf.ac.at)</u></a></p> <p>For information on submitting an application from abroad see the FWF Website at <a href="http://Applications from abroad (fwf.ac.at)"><u>Applications from abroad (fwf.ac.at)</u></a></p> |
| <p><b>Submission of other information at the national level</b></p>                | <p>See above</p>   |
| <p><b>Submission of financial and scientific reports at the national level</b></p> | <p>n.a.</p>  |
| <p><b>Further guidance</b></p>   | <p>Researchers are eligible to apply if their publication record over the last five years has been internationally visible and if their current career stage is commensurate with the career progression expected in their field. The following criteria are decisive in assessing their publication record—documented in the “Publication list” and in initiating the review process:</p> <p>Quality assurance: Most relevant in assessing the applicant’s publication record are those publications that have undergone a quality assurance procedure in line with international standards (peer review or an equivalent procedure; in the natural and life sciences, peer reviews expected). Journals must usually be listed in Web of Science, Scopus, or the Directory of Open Access Journals (DOAJ). In the case of journals not listed in these databases, or monographs, edited volumes, contributions to edited volumes, or other publication types, the applicant must provide a link to the publisher’s website, describing the respective quality assurance procedure. If no description should be available, it is the</p>   |

applicant's responsibility to provide evidence that the publication has been subject to an appropriate quality assurance procedure.

International visibility: Most of the applicant's publications must have a wider than national reach. In the natural sciences, life sciences, and social sciences, most of the publications listed must be in English.

Number/scope and quality of the applicant's publications must be commensurate with the expected career progression and the field concerned. At least two publications must have undergone a quality assurance procedure and must be internationally visible with a substantial and independent contribution on the part of the applicant. At least one publication with first, last or corresponding authorship in the life sciences is required.

Should an applicant fail to meet one or more of the above criteria, the applicant must include an explanation together with the application. In cases of doubt, the decision-making bodies of the FWF shall decide whether the research qualifications are adequate.

|  |   |
|--|---|
| Country  | Belgium   |
| Funding organisation   | Fund for Scientific Research-FNRS   |
| National contact person  | Dr. Agnès Roba (+32 2 504 9236)<br>Dr. Florence Quist (+32 2 504 9351)<br><a href="mailto:international@frs-fnrs.be">international@frs-fnrs.be</a>  |
| Funding commitment   | 300.000 €   |
| Anticipated number of fundable proposals                             | 1   |
| Maximum/ Minimum funding per grant awarded to a project partner      | 300.000 € per project for 3 years   |
| Eligibility of partners  | All eligibility rules and criteria can be found in the <a href="#">PINT-MULTI regulations</a> .   |
| Eligibility of costs, types and their caps                           | All eligibility rules and criteria can be found in the <a href="#">PINT-MULTI regulations</a> . Please note that <b>personnel costs (Article III.6) have an annual average cap of 80,000 euros for this call.</b><br><b>Clinical studies are not eligible for funding by the F.R.S.-FNRS</b><br><b>“Overhead” is not an eligible cost.</b> If the project is selected for funding, these costs will be subject to a separate agreement between the institution of the beneficiary and the F.R.S.-FNRS.                        |
| Submission of the proposal at the national level                     | <b>Applicants to F.R.S.-FNRS funding must provide basic administrative data by submitting an administrative application on <a href="#">e-space</a> within 5 working days after the general deadline of the ERA4Health JTC3 call to be eligible.</b><br>Please select the “PINT-MULTI” funding instrument when creating the administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS. |
| Submission of other information at the national level                | As described in the <a href="#">PINT-MULTI regulations</a> .  |
| Submission of financial and scientific reports at the national level | As described in the <a href="#">PINT-MULTI regulations</a> .  |
| Further guidance   | <a href="https://www.frs-fnrs.be/fr/calendrier-des-appels">https://www.frs-fnrs.be/fr/calendrier-des-appels</a>   |

|  |  |
|--|--|
| <b>Country</b>   | <b>Belgium</b>   |
| <b>Funding organisation</b>  | <b>The Research Foundation – Flanders (FWO)</b>  |
| <b>National contact person</b>   | Toon Monbaliu (FO)                      Kristien Peeters (SBO)<br><a href="mailto:europa@fwo.be">europa@fwo.be</a> <a href="mailto:kristien.peeters@fwo.be">kristien.peeters@fwo.be</a><br>+32 (0)2 550 15 70                      +32 (0)2 550 15 95  |
| <b>Funding commitment</b>  | 700.000 EUR  |
| <b>Anticipated number of fundable proposals</b>                        | 2-3  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | Maximum 350.000 EUR per project/consortium (overhead included).  |
| <b>Eligibility of partners</b>   | <p>The FWO integrates two of its <u>funding channels</u> within this multilateral framework. The choice of funding channel depends on the <u>type of project</u> the researchers from Flanders wish to undertake.</p> <p>The eligibility of research institutions and its researchers can be verified in the relevant and respective chosen funding channels regulations, which can be consulted on the FWO website:</p> <ul style="list-style-type: none"> <li>- <a href="#">FWO Research Projects (FO)</a></li> <li>- <a href="#">Strategic Basic Research (SBO)</a></li> </ul>  |
| <b>Eligibility of costs, types and their caps</b>                      | <p>The respective funding channel regulations apply (see links to national rules above), and both are capped at max. 350.000 EUR per project/consortium (incl. overhead, for which the calculation method diverges per funding channel).</p> <p>The FWO foresees a budget of 700.000 EUR, which allows for the funding of at least 2 projects.</p> <p>For the overhead calculation, the fundamental (FO) and strategic research projects (SBO) entail the same approach: a structural overhead rate should be applied on the total project costs, with an overhead rate of 6% for ‘FO’ projects, and a 17% overhead rate for ‘SBO’ projects. Some practical examples:</p> <ul style="list-style-type: none"> <li>• FO: the sum of all costs (personnel, consumables, travel, subcontracting, etc.) amounts to 200.000 EUR, then the overhead will amount to 12.000 EUR (6% of 200.000 EUR) and the total requested cost is 212.000 EUR. This total requested cost may never exceed the max. available amount of 350.000 EUR.</li> <li>• SBO: the sum of all costs (personnel, consumables, travel, subcontracting, etc.) amounts to 200.000 EUR, then the overhead will amount to 34.000 EUR (17% of 200.000 EUR) and the total</li> </ul> |

|  |  |
|--|--|
|  | <p>requested cost is 234.000 EUR. This total requested cost may never exceed the max. available amount of 350.000 EUR.</p> <p><b>The FWO funds up to <u>pre-clinical research</u>.</b></p>   |
| <p><b>Submission of the proposal at the national level</b></p>                     | <p><b>!! NEW !!</b></p> <p>Applicants for FWO funding must submit a <b>mandatory administrative application via the FWO e-portal</b>. For fundamental research projects (FO) select the application type: “Research projects – European programme fundamental research”. For strategic basis research projects (SBO) select the application type: “Research projects – European programme strategic basic research”. In case the consortium includes more than one partner requesting funding from FWO, a <u>single online form</u> should be submitted containing all relevant information from the different Flemish partners.</p> <p>The deadline to submit the administrative application to the FWO is identical to the deadline of the joint transnational call (preproposal stage). To ensure the eligibility of the proposal, it is recommended to consult the FWO administration at least one week in advance.</p> <p><b>Failure to comply with these requirements can lead to ineligibility.</b></p>   |
| <p><b>Submission of financial and scientific reports at the national level</b></p> | <ul style="list-style-type: none"> <li>• No additional, national scientific reporting is required: the ERA4Health call reporting requirements suffice in this regard.</li> <li>• Financial reporting is similar to the national framework. One additional feature: at the end of the project the FWO will ask for a cost statement, in the light of its own reporting requirements.</li> </ul>   |
| <p><b>Further guidance</b></p>   | <ul style="list-style-type: none"> <li>• Participation in this call does not interfere with the ‘regular/national’ project submission framework, and is consequently not taken into account for calculating the max. available number of new applications and running projects combined. However, <b>researchers can only participate within 2 different international consortia in this call</b> (and only once if they act as coordinator in one of the proposals).</li> <li>• Projects aiming at the development of a spin-off company are not eligible in this context.</li> <li>• The <b>project duration is limited to 36 months</b>, which implies the funding has to be budgeted and spent accordingly. An automatic prolongation and using positive (financial) balances after the end date is not applicable in this framework. As such article 28 of the <a href="#">FWO Research Projects</a> and article 14 of the <a href="#">Strategic Basic Research (SBO)</a> regulations do not apply in this context.</li> <li>• The PI, for each of the participating institutions applying for FWO funds, must hold an <b>appointment that fully covers the duration of the research project</b>. Linked to this, and when it comes to the <a href="#">FWO</a></li> </ul> |

[research project regulations \(FO\)](#): article 10, §7 is not applicable in this framework. I.e. supervisors (-spokespersons), or coordinators/consortium partners who are granted **emeritus** status during the calendar year of submission of the project application or during the duration of the project are **not eligible**.

- It is strongly advised to contact the FWO contact persons mentioned above, in order not to jeopardize any research projects/consortia.

|   |   |
|---|---|
| <b>Country</b>  | <b>Denmark</b>  |
| <b>Funding organisation</b>   | <b>Innovation Fund Denmark (IFD)</b>  |
| <b>National contact person</b>  | Daniel G. Marques<br>E-mail: <a href="mailto:daniel.g.marques@innofond.dk">daniel.g.marques@innofond.dk</a><br>Tel. +45 6190 5006<br>or internationale@innofond.dk  |
| <b>Funding commitment</b>   | 1.000.000 EUR   |
| <b>Anticipated number of fundable proposals</b>                             | 2-5   |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b>      | The co-financing from Innovation Fund Denmark is a maximum of 500.000 € per <u>project</u> and a maximum 300.000 € per Danish <u>partner</u> .<br>Maximum funding rates may vary between 35-90% of the <u>partner's budgeted costs</u> , please see <a href="#">Guidelines for international projects</a> . |
| <b>Eligibility of partners</b>  | All Danish organizations directly involved in activities in the projects are eligible as applicants to the innovation Fund Denmark  |
| <b>Eligibility of costs, types and their caps</b>                           | Eligible cost categories for Danish partners: <ul style="list-style-type: none"> <li>• Personnel costs (e.g. salaries);</li> <li>• Operational costs (e.g. travels, materials, etc.);</li> <li>• Indirect costs (i.e. overhead, if eligible);</li> <li>• Subcontracting (to a limited extent).</li> </ul>   |
| <b>Submission of the proposal at the national level</b>                     | After the application deadline Innovation Fund Denmark will, via our national e-grant platform, invite applicants to upload a pdf of the application with annexes. The invitation is normally sent approximately 4 weeks after the application deadline.  |
| <b>Submission of other information at the national level</b>                | Danish industrial partners will in addition be requested to upload the following declarations and documents: 'SME declaration', 'No undertaking in difficulty', 'Ability to co-finance' and if funding via <i>de minimis</i> , then a ' <i>de minimis</i> aid compliance form'.                             |
| <b>Submission of financial and scientific reports at the national level</b> | Scientific and financial reports will be requested via our national e-grant platform every six months.  |
| <b>Further guidance</b>   | Please see our <a href="#">Guidelines for international projects</a> .  |

|  |  |
|--|--|
| <b>Country</b>   | <b>Estonia</b>   |
| <b>Funding organisation</b>  | <b>Estonian Research Council</b>   |
| <b>National contact person</b>   | <p>Margit Suuroja<br/> <a href="mailto:margit.suuroja@etag.ee">margit.suuroja@etag.ee</a><br/> +372 731 7360</p> <p>Argo Soon<br/> <a href="mailto:argo.soon@etag.ee">argo.soon@etag.ee</a><br/> +372 515 3424</p>   |
| <b>Funding commitment</b>  | 150 000 €  |
| <b>Anticipated number of fundable proposals</b>                        | 1  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | 150 000 €  |
| <b>Eligibility of partners</b>   | <p>The Host Institution may be any legal entity that is registered and located in Estonia and has an Estonian bank account.</p> <p>The Principal Investigator:</p> <p>1.2.1 must have an updated public profile in the Estonian Research Information System (ETIS) by the submission deadline;</p> <p>1.2.2 must hold a doctoral degree or an equivalent qualification. The degree must be awarded by the submission deadline of the grant application at the latest;</p> <p>1.2.3 must have published at least three articles that comply with the requirements of Clause 1.1 of the ETIS classification of publications, or at least five articles that comply with the requirements of Clauses 1.1, 1.2, 2.1 or 3.1, within the last five calendar years prior to the proposal submission deadline. International patents are equalled with publications specified under Clause 1.1. A monograph (ETIS Clause 2.1) is equalled with three publications specified in Clause 1.1 if the number of authors is three or fewer. If the applicant has been on pregnancy and maternity or parental leave or performed compulsory service in the Defence Forces, or has another good reason, they can request the publication period requirement to be extended by the relevant period of time.</p> <p>If the Principal Investigator has received the PhD degree outside Estonia, its correspondence to an Estonian doctoral degree must be recognised by either the Estonian ENIC-NARIC Centre or the Host Institution in accordance with the Regulation of the Government of the Republic of April 6, 2006, No. 89 "Evaluation and academic recognition of documents proving foreign education and the name of the qualification awarded in the foreign</p> |

|   |  |
|---|--|
|   | education system terms and conditions of use". The Funding Organisation may ask for a relevant Evaluation Report.  |
| <b>Eligibility of costs, types and their caps</b>       | <p>1. Personnel costs are monthly salaries with social security charges and all other statutory costs of the project participants, calculated according to their commitment and in proportion to their total workload at their Host Institution.</p> <p>2. Other direct costs are:</p> <ul style="list-style-type: none"> <li>- travel costs that may cover expenses for transport, accommodation, daily allowances and travel insurance;</li> <li>- consumables and minor equipment related to the project;</li> <li>- publication and dissemination of project results;</li> <li>- organising meetings, seminars or conferences (room rent, catering);</li> <li>- fees for participating in scientific forums, conferences and other events related to the project;</li> <li>- patent costs;</li> <li>- all other costs that are identifiable as clearly required for carrying out the project (e.g. translation, copy editing, webpage hosting, etc.) and comply with the eligible costs.</li> </ul> <p>3. Subcontracting costs should cover only additional or complementary research related tasks (e.g. analyses, conducting surveys, building a prototype, etc.) performed by third parties. Subcontracting costs should not be included in the overhead calculation. The activities and budget should be described in the proposal. Core project tasks should not be subcontracted. Subcontracting costs may not exceed 15% of the total costs.</p> <p>4. Indirect costs (overhead) may not exceed 15% of the personnel costs and should cover the general expenses of the Host Institution. Costs for equipment and services intended for public use (e.g. a copy machine or a printer that is publicly used, phone bills, copy service, etc.) should be covered from the overhead.</p> <p>5. Double funding of activities is not acceptable.</p> <p>6. If several Estonian institutions participate in one proposal, the sum of their requested budgets may not exceed the maximum contribution of the respective national Funding Organisation indicated in the call documents.</p> <p>7. State Aid</p> <p>EU Regulations on State aid and de minimis aid must be taken into account when requesting funding.</p> |
| <b>Submission of the proposal at the national level</b> | No additional documents should be submitted to ETAG during the submission phase.   |

|   |   |
|---|---|
| <b>Submission of other information at the national level</b>                | No additional documents should be submitted to ETAG during the submission phase.  |
| <b>Submission of financial and scientific reports at the national level</b> | Financial reports are required.   |
| <b>Further guidance</b>   | <a href="https://etag.ee/wp-content/uploads/2022/07/Vastavusnouded-RV-uhiskonkurssidel_-EN_veebr.2023.pdf">https://etag.ee/wp-content/uploads/2022/07/Vastavusnouded-RV-uhiskonkurssidel_-EN_veebr.2023.pdf</a> |

|  |   |
|--|---|
| <b>Country</b>   | <b>France</b>   |
| <b>Funding organisation</b>  | <b>French Research Funding Agency</b>   |
| <b>National contact person</b>   | Dr. Martine Batoux<br>Phone number: +33 1 73 54 81 40<br><a href="mailto:Era4healthcall@agencerecherche.fr">Era4healthcall@agencerecherche.fr</a>   |
| <b>Funding commitment</b>  | 1 250 000 €   |
| <b>Anticipated number of fundable proposals</b>                        | 3-4   |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | ANR funding will be limited to 250 000 € per French applicant. For a French team taking over the coordination of the project, the maximum budget can be increased up to 300 000 €.<br><br>Minimum amount per partner: 15 000 €.<br><br>Maximum amount per project: 400 000 €.   |
| <b>Eligibility of partners</b>   | ANR may finance fundamental research, industrial research and experimental developments. Funded Partners must have their primary establishment in France and/or in the EU with a secondary establishment in France.<br>Please note that companies <a href="#">with economic difficulties</a> are excluded from ANR subventions.<br>Countries subject to sanctions applicable to the research field by the European Union authorities are excluded from this call. Projects involving Partners established in these countries will be declared ineligible by the ANR. At the date of publication, these exclusions concern partners from the following countries Russia, Belarus. This list may evolve in case of new sanctions decided by the European Union.   |
| <b>Eligibility of costs, types and their caps</b>                      | Standard ANR funding rules apply for eligible costs, unless stated otherwise in the Annex « <i>Modalités pour les partenaires sollicitant une aide de l'ANR</i> ». These rules are specified in ANR's "ANR Funding regulations" along with the explanatory note available at: <a href="https://anr.fr/fileadmin/documents/2017/ANR-RF-Fiche-COUTS.pdf">https://anr.fr/fileadmin/documents/2017/ANR-RF-Fiche-COUTS.pdf</a><br>Eligible costs (e.g.: personnel costs, costs of instruments and equipment, additional overheads (13,5%) and other operating expenses incurred directly as a result of the research project such as, for instance: travel costs) and funding rates vary based on the type of research and research partner. Please note that expenses related to permanent staff stipends are not eligible for the Beneficiaries "à coût marginal". |
| <b>Submission of the proposal at the national level</b>                | No additional documents should be submitted to ANR during the submission phase.   |

|   |  |
|---|--|
| <b>Submission of other information at the national level</b>                | When a project is selected for funding, administrative and financial data of the partners funded by ANR must be entered by the applicant on the ANR platform.  |
| <b>Submission of financial and scientific reports at the national level</b> | <p>The ANR funded partners must communicate to ANR the required Scientific reports, Consortium Agreement, Data management plans according to the funding contract and as required to the project coordinator by ERA4Health.</p> <p>Financial reports must be communicated to ANR according to the provisions of ANR Funding regulations.</p> <p>If applicable, Declarations of Due Diligence for the financed projects (Nagoya Protocol) must also be transmitted to ANR in due time.</p>  |
| <b>Further guidance</b>   | <p>ANR does not allow double application nor double funding and will not finance projects or part of projects that have been funded through other calls.</p> <p>See Annex « <i>Modalités pour les partenaires sollicitant une aide de l'ANR</i> » for additional ANR rules at <a href="https://anr.fr/fileadmin/aap-ERA4Health-nutribrain-2024-annexe-fr.pdf">https://anr.fr/fileadmin/aap-ERA4Health-nutribrain-2024-annexe-fr.pdf</a></p> <p>The above-mentioned terms and conditions are only summarized translations of those entailed in the ANR Funding regulations and in the Annex. In case of inconsistencies, the terms of the ANR Funding regulations and the Annex shall prevail. Please consult these documents for more details.</p> |

|  |  |
|--|--|
| <b>Country</b>   | <b>Germany</b>   |
| <b>Funding organisation</b>  | <b>Federal Ministry for Education and Research (BMBF) represented by the Programme Management Agency in the German Aerospace Centre (DLR-PT)</b>   |
| <b>National contact person</b>   | <p>Name : Dr. Svenja Finck<br/>Dr. Bärbel Edelman-Stephan</p> <p>Phone: +49 228 3821 1877<br/>+49 228 3821 1639</p> <p>E-mail: <a href="mailto:era4health@dlr.de">era4health@dlr.de</a></p> <p>Address: DLR PT, on behalf of the BMBF<br/>Heinrich-Konen-Str. 1<br/>53227 Bonn<br/>Germany</p>   |
| <b>Funding commitment</b>  | up to 2.0 M€   |
| <b>Anticipated number of fundable proposals</b>                        | 5 - 6  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | Up to 350.000€ per consortium (overhead costs included). <b>Only one German partner per consortium is allowed. The applicants are not allowed to participate in more than one research proposal.</b>   |
| <b>Eligibility of partners</b>   | Eligible applicants are researchers or research groups from German universities, German university hospitals, German non-university research institutes and industry/SMEs registered in Germany (subject to certain conditions). For specific conditions see also link to German version of the call below.  |
| <b>Eligibility of costs, types and their caps</b>                      | <p>The following costs are eligible for funding (details see German version of the call):</p> <ul style="list-style-type: none"> <li>- Research costs (e.g. personnel, consumables)</li> <li>- Travel &amp; networking costs</li> <li>- Communication &amp; dissemination costs</li> <li>- Overhead costs (“Projektpauschale”)</li> </ul> <p>Overheads are eligible according to standard BMBF regulations.</p> <p>Funding rates for universities, university hospitals and non-university research institutes can be up to 100% of their costs. Research institutions that receive basic funding from the federal and/or state governments can only receive project funding for their additional project-related expenses</p> |

|   |   |
|---|---|
|   | or costs in addition to their institutional funding. Industry can be funded with a maximum of 80% of their cost.  |
| <b>Submission of the proposal at the national level</b>                     | On request in case of a positive funding recommendation   |
| <b>Submission of other information at the national level</b>                | On request in case of a positive funding recommendation   |
| <b>Submission of financial and scientific reports at the national level</b> | On request in case of a positive funding recommendation   |
| <b>Further guidance</b>   | See also German version of the call:<br><a href="https://www.gesundheitsforschung-bmbf.de/de/17006.php">https://www.gesundheitsforschung-bmbf.de/de/17006.php</a> |

|  |   |
|--|---|
| <b>Country</b>   | <b>Ireland</b>  |
| <b>Funding organisation</b>  | <b>Health Research Board</b>  |
| <b>National contact person</b>   | Dr Siobhán Hackett<br>Dr Amanda Daly<br>Email: <a href="mailto:eujointprogrammes@hrb.ie">eujointprogrammes@hrb.ie</a>   |
| <b>Funding commitment</b>  | €430,000 (inclusive of overheads) for partners<br>This may be raised to €530,000 for coordinators.  |
| <b>Anticipated number of fundable proposals</b>                        | 1–2   |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | <p><b>Maximum funding is:</b></p> <p><b>For Partners:</b><br/>€330,000 direct costs;<br/>€430,000 including overheads.</p> <p><b>For Coordinators:</b><br/>€405,000 direct costs (with the additional €75,000 for coordination-specific activities);<br/>€530,000 including overheads.</p> <p>Please see HRB’s dedicated scheme page on <a href="#">HRB’s funding page</a> for further Guidance and FAQ specific to applicants based in Ireland.</p>  |
| <b>Eligibility of partners</b>   | <p>Lead applicants (Principal Investigators) based in Ireland must be from a recognised HRB Host Institution (<a href="#">Policy on Approval of HRB Host Institutions</a>).</p> <p>Partners classed as ‘Enterprise’ cannot be in receipt of HRB funding.</p> <p>Please see HRB’s dedicated scheme page on <a href="#">HRB’s funding page</a> for Guidance and FAQ specific to applicants based in Ireland.</p>  |
| <b>Eligibility of costs, types and their caps</b>                      | <p>Funding available is inclusive of overheads and pension contributions</p> <ul style="list-style-type: none"> <li>• Salary related costs</li> <li>• Direct running costs, including patient-related costs and costs to support interventional studies</li> <li>• Patient and Public Involvement (PPI) costs</li> <li>• Small equipment costs (€10,000)</li> <li>• Travel</li> <li>• FAIR data management costs</li> <li>• Dissemination and knowledge exchange costs</li> </ul> <p>For more information please see HRB’s guidance on the dedicated scheme page on <a href="#">HRB’s funding page</a>.</p> |
| <b>Submission of the proposal at the national level</b>                | No additional requirements  |
| <b>Submission of other information at the national level</b>           | <p>Applicants will have to complete HRB’s Budget and Deliverables templates. These will be supplied after submission.</p> <p>Applicants must submit a short information form at submission to provide details on PI’s track record for eligibility checks.</p>  |

|  |   |
|--|---|
| <p><b>Submission of financial and scientific reports at the national level</b></p> | <p>HRB grant holders are required to submit grant reports as outlined in their grant contracts and the most recent <a href="#">HRB General Terms and Conditions for Research Awards</a>.</p> <p>These include Annual and Final reports.</p>   |
| <p><b>Further guidance</b></p>   | <p>All Irish partners who are undertaking feasibility and/or interventional studies must adhere to the <a href="#">HRB Clinical Trial and Interventions Research Governance Policy</a>.</p> <p>In projects where consortia include enterprise partners, applicants applying to HRB for funding will be advised that funding awarded will be subject to, and must comply with, State aid rules and conditions of the European Commission General Block Exemption Regulation (GBER).</p> <p>All applicants should contact the HRB with any queries regarding the requirements of this policy.</p> |

|   |   |
|---|---|
| <b>Country</b>  | <b>Israel</b>   |
| <b>Funding organisation</b>   | <b>Ministry of Health</b>   |
| <b>National contact person</b>  | Dr. Irit Allon Phone: +972 (0)2 5082167 ; Email: <a href="mailto:irit.allon@moh.health.gov.il">irit.allon@moh.health.gov.il</a><br>Chief Scientist Office, Ministry of Health<br>Dr. Adelina Ovcharenko Phone: +972 (0) 543138655; Email: <a href="mailto:adelina@midgam.org">adelina@midgam.org</a> Chief Scientist Office, Ministry of Health |
| <b>Funding commitment</b>   | 320,000 €   |
| <b>Anticipated number of fundable proposals</b>                             | Up to 2 Projects  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b>      | Up to 140,000 € Additional 40,000 € for coordination  |
| <b>Eligibility of partners</b>  | Position in a university, research center or hospital. Research authority must approve position prior to submission.  |
| <b>Eligibility of costs, types and their caps</b>                           | Materials and consumables; Travel and hosting (up to 10%); No salaries for applicants; No heavy equipment, Institutional overhead 10%.  |
| <b>Submission of the proposal at the national level</b>                     | Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including budget distribution. No submission of abstract can result in declaration of the consortium as ineligible.  |
| <b>Submission of other information at the national level</b>                | If the application involves human or animal experiments, bioethics approvals must be submitted with the application.  |
| <b>Submission of financial and scientific reports at the national level</b> | Required annually.  |
| <b>Further guidance</b>   | Please see detailed instructions of application at the national level and reporting at <a href="http://www.health.gov.il/research-fund">http://www.health.gov.il/research-fund</a>  |

|   |   |
|---|---|
| <b>Country</b>  | Italy   |
| <b>Funding organisation</b>   | Italian Ministry of Health (IT-MoH) <a href="http://www.salute.gov.it">www.salute.gov.it</a>  |
| <b>National contact person</b>                                      | Gaetano Guglielmi – Head Office 3 – Health Research - <a href="mailto:g.guglielmi@sanita.it">g.guglielmi@sanita.it</a><br>Francesca Turco –Scientific Officer - <a href="mailto:f.turco@sanita.it">f.turco@sanita.it</a><br>Chiara Ciccarelli – NCP and Programme Officer- <a href="mailto:c.ciccarelli@sanita.it">c.ciccarelli@sanita.it</a>   |
| <b>Funding commitment</b>   | 1,5 M €   |
| <b>Anticipated number of fundable proposals</b>                     | 4   |
| <b>Maximum/Minimum funding per grant awarded to project partner</b> | Max. 400K € per project   |
| <b>Eligibility of partners</b>                                      | <p>Only IRCCS (Istituti di Ricovero e Cura a Carattere Scientifico) researchers are eligible to apply.</p> <p><b>Not fundable:</b> Universities, other research Institutes, companies.</p> <p>No more than two Italian PIs (Principal Investigators) are eligible to apply for the same project.</p> <p>Simultaneous PI participation in different 2023 JTCs funded by the Ministry of Health is not allowed.</p> |

|  |   |
|--|---|
| <p><b>Eligibility of costs, types and their caps</b></p>                           | <p>Direct Costs:</p> <ul style="list-style-type: none"> <li>• Personnel (only temporary contracts, max 50%);</li> <li>• Consumables;</li> <li>• Animals;</li> <li>• Equipment (only on hire);</li> <li>• Travel (max 10%);</li> <li>• Documentation (Max 1%)</li> </ul> <p>Indirect Costs:</p> <ul style="list-style-type: none"> <li>• Overhead (max 10%, included in the total); Other indirect costs are not eligible.</li> </ul> <p>Transfer of eligible funds abroad is not allowed.</p>   |
|  | <p>Subcontracts are allowed only upon approval, by presenting via Workflow – code ER, a request together with the National pre-eligibility form, the latest 20 days before the deadline of the pre-proposal submission.</p> <p>Italian PAOs can be funded as a sub-contractor of an IRCCS if they fulfil the eligibility criteria of the EC. The maximum cost eligible for a sub-contract is 25.000 Euros (from the IRCCS Budget).</p> <p>Italian PAOs can still participate in Consortia as “Collaborators” with their own funds.</p>  |
| <p><b>Submission of the proposal at the national level</b></p>                     | <p>In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicant prior to the submission of the proposals. To this end, <b>it is mandatory that the applicants fill out and return to the IT-MoH a pre-submission eligibility check form through their IRCCS, using WFR System-&gt; ER communication code</b>, before submitting their proposal to the Joint Call Secretariat.</p> <p>It is strongly recommended that the form, completed and duly signed, is returned <b>at least 10 working days before the proposal submission deadline</b>. Applicants will be sent written notification of their eligibility status. Changes in acronyms and budgets provided in the pre-submission eligibility check are not allowed.</p> <p>The pre-eligibility form can be downloaded here: <a href="https://www.salute.gov.it/imgs/C_17_pagineAree_4441_0_file.pdf">https://www.salute.gov.it/imgs/C_17_pagineAree_4441_0_file.pdf</a></p> |
| <p><b>Submission of other information at the national level</b></p>                | <p>-</p>  |
| <p><b>Submission of financial and scientific reports at the national level</b></p> | <p>Submission of annual scientific and financial reports at the national level will be required according to the rules of the Ministry of Health (Ricerca Corrente).</p>  |

**Further  
guidance**

Further information on the rules of the Ministry of Health can be requested to the national contact persons.

|  |   |
|--|---|
| <b>Country</b>   | <b>Italy</b>  |
| <b>Funding organisation</b>  | <b>Ministero dell'Università e della Ricerca (MUR)</b>  |
| <b>National contact person</b>   | Sara Cella: <a href="mailto:sara.cella@est.mur.gov.it">sara.cella@est.mur.gov.it</a><br>Aldo Covello: <a href="mailto:aldo.covello@mur.gov.it">aldo.covello@mur.gov.it</a>  |
| <b>Funding commitment</b>  | 1.000.000 €   |
| <b>Anticipated number of fundable proposals</b>                        | 4   |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | 250.000 € per project (not per partner)   |
| <b>Eligibility of partners</b>   | <p>The following entities are eligible, providing that they have stable organization in Italy: enterprises including foundations and non-economic entities, universities, research institutions, research organizations in accordance with EU Reg. n. 651/2014 of the European Commission - June 17, 2014, patient advocacy organizations, local and regional administrations;</p> <p>Any participant, in order to be eligible, must comply with the eligibility criteria listed in the "Avviso integrativo nazionale".</p>   |
| <b>Eligibility of costs, types and their caps</b>                      | <p>All costs incurred during the lifetime of the project under the following categories are eligible:</p> <ul style="list-style-type: none"> <li>• A) Personnel,</li> <li>• B) Consulting and equivalent services (subcontracting)</li> <li>• C.1) Travel and subsistence</li> <li>• C.2) Equipment</li> <li>• C.3) Other goods and Services</li> <li>• E) Indirect Costs/Overheads ("Spese generali") calculated at 25% flat rate of all direct costs excluding cost category B) Consulting and equivalent services [ E) = 25% of A) + C.1) + C.2) + C.3 ].</li> </ul> <p>All activities classifiable as Basic research, Industrial research and Experimental development are eligible for funding. Furthermore, Basic Research and Industrial research activities must be predominant with respect to Experimental development activities (in terms of costs).</p> <p>The amount of funding which can be granted to each beneficiary is calculated multiplying the eligible costs for the funding rates listed hereafter:</p> <p>Basic research: 70%</p> <p>Industrial Research: 70%</p> <p>Experimental Development: 25%</p> |

|  |   |
|--|---|
| <p><b>Submission of the proposal at the national level</b></p>                     | <p>In addition to the project proposal, which shall be submitted at European level, the Italian participants are requested to submit a national additional application to MUR, through the national web platform, available at the following link: <a href="https://banditransnazionali-miur.cineca.it">https://banditransnazionali-miur.cineca.it</a></p> <p><b>This national additional application must be submitted by the same deadline established in the international joint call for pre-proposal submission. Any participant who does not submit its national documents by the deadline will be considered not eligible for funding.</b></p> <p>More information on the national documentation to be submitted to MUR is available at the web page dedicated to the partnership ERA4Health:<br/><a href="http://www.ricercainternazionale.miur.it/era/european-partnership-2021-27/era4health.aspx">http://www.ricercainternazionale.miur.it/era/european-partnership-2021-27/era4health.aspx</a></p> <p>It is strongly recommended to contact the National Contact Persons already in early stage of project preparation.</p> <p>The admission for funding is subject to the adoption of the necessary accounting and administrative measures for the allocation of the resources.</p> <p>Funded participants will be requested to submit financial and scientific reports to MUR.</p> <p>The criteria and provisions provided herewith are intended only for informative purposes. The complete list of criteria and provisions legally valid, which must be respected by all the Italian participants, is included in the “Avviso integrativo nazionale”, which will be published on the MUR website, and in the applicable Italian laws.</p> |
| <p><b>Submission of other information at the national level</b></p>                | <p>Other information may be requested for the preparation and signature of the contract</p>   |
| <p><b>Submission of financial and scientific reports at the national level</b></p> | <p>During the project execution and after the end of the projects, financial and scientific reports are requested to verify the project advancement and the achievement of the project results.</p>   |
| <p><b>Further guidance</b></p>   | <p>Relevant documents:</p> <ul style="list-style-type: none"> <li>- Decreto legge n. 83/2012</li> <li>- Decreto Ministeriale n. 1314 del 14 dicembre 2021</li> <li>- Decreto Ministeriale n. 1368 del 24 dicembre 2021</li> <li>- Avviso integrativo nazionale</li> </ul> <p>Useful Links:</p>  |

**National website:**

<http://www.ricercainternazionale.miur.it/era/european-partnership-2021-27/era4health.aspx>

**National submission platform:** <https://banditransnazionali-miur.cineca.it>

|  |   |
|--|---|
| <b>Country</b>   | <b>Latvia</b>   |
| <b>Funding organisation</b>  | <b>Latvian Council of Science (LCS)</b>   |
| <b>National contact person</b>   | <p>Maija Bundule<br/>E-mail: <a href="mailto:Maija.Bundule@lzp.gov.lv">Maija.Bundule@lzp.gov.lv</a><br/>Tel: +371- 26514481</p> <p>Uldis Berkis<br/>E-mail: <a href="mailto:Uldis.Berkis@lzp.gov.lv">Uldis.Berkis@lzp.gov.lv</a><br/>Tel.: +371-29472349</p>  |
| <b>Funding commitment</b>  | 0,45M EUR   |
| <b>Anticipated number of fundable proposals</b>                        | 2   |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | <p>Maximum funding for a partner is 100.000 EUR per year<br/>Funding rates under Regulation EC 651/2014 shall be respected in case of state aid<br/>Maximum 2 Latvian partners per proposal allowed</p>   |
| <b>Eligibility of partners</b>   | <p>Only the following legal persons are eligible:</p> <p>1) Research institutions registered in the Latvian Registry of Scientific Institutions, e.g.<br/>- Research Institutes<br/>- Universities<br/>And must have the status of Research and knowledge dissemination organization (Regulation EC 651/2014)</p> <p>2) Business enterprises entered into the Latvian Commercial registry as companies, assumed they are eligible to do the specific research and have specific capacity and resources to do the research in Latvia and have their main activity in Latvia. Limitations of EU legislation apply (R651/2014) together with financial reporting requirements, in this case this is state aid. Two previous statements with sworn auditor's approval should be provided and they must reflect the correspondence to the regulation as well as prove the evidence of previous scientific activity and presence of capacity.</p> |
| <b>Eligibility of costs, types and their caps</b>                      | <ul style="list-style-type: none"> <li>• Personnel costs incl. taxes;</li> <li>• Consumables;</li> <li>• Subcontracts (up to 25% of direct costs), needs detailed justification, includes all external services, project core activities cannot be subcontracted;</li> <li>• Equipment (only depreciation costs during project directly attributable to project tasks);</li> <li>• Replaceable and fully consumable during project elements of equipment (e.g. electrodes);</li> <li>• Travels (according to travel plan);</li> </ul> <p>Indirect costs (up to 25% of direct costs excluding subcontracting).</p>   |
| <b>Submission of the proposal at the national level</b>                | No  |
| <b>Submission of other information at the national level</b>           | To receive funding by LCS, Consortium agreement duly signed should be presented. Enterprises shall provide audited statements of 2 previous closed financial periods on request.  |

|   |  |
|---|--|
|   | Final audit according to the LCS regulations.  |
| <b>Submission of financial and scientific reports at the national level</b> | Annual or in some cases half-annual financial and scientific reporting is mandatory.   |
| <b>Further guidance</b>   | <p>Support is provided according to Provisions Nr 259, 26.05.2015 of the Latvian Cabinet of Ministers (<a href="http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibaistarptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma">http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibaistarptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma</a>)</p> <p>These provisions should be respected without exceptions. The maximum rates should respect the Provisions. The requirements in the provisions to specific applicant groups must be respected.</p> <p>LCS cannot fund implementation support, nor training activities.</p> <p>LCS is funding only research.</p> |

|   |   |
|---|---|
| <b>Country</b>  | <b>Lithuania</b>  |
| <b>Funding organisation</b>   | <b>Research Council of Lithuania (Lietuvos mokslo taryba), LMT</b>  |
| <b>National contact person</b>  | Živilė Ruželė<br>E-mail: <a href="mailto:zivile.ruzele@lmt.lt">zivile.ruzele@lmt.lt</a> ;<br>Tel. +37067614383  |
| <b>Funding commitment</b>   | 300 000 Eur   |
| <b>Anticipated number of fundable proposals</b>                             | 1-2 projects  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b>      | Within a single project proposal, the maximum funding can be up to EUR 150 000 for a consortium partner; up to EUR 200 000 for a coordinator/2 eligible LT partners in a consortium or up to EUR 250 000 for a coordinator and 1 eligible LT partner in a consortium  |
| <b>Eligibility of partners</b>  | Eligible for funding institutions are Lithuanian research and higher education institutions that are included in the Register of Education and Research institutions, public healthcare institutions, academy of science mentioned in the state Law on Science and Studies, other state public institutions such as National libraries, archives, museums. Beneficiary institution (grant holder) manage the state budget funds allocated to the project following the rules stated in the legal acts, as well as representing the project partners (if applicable 'project partner' means public or private legal entity that, together with the eligible institution, created the conditions for project implementation). |
| <b>Eligibility of costs, types and their caps</b>                           | Only costs (direct) generated during the lifetime of the project, related to project are eligible. Direct costs: personnel, travel, purchase (assets, services, consumables), subcontracting.<br><br>Overheads (indirect costs): up to 20 % from direct costs.  |
| <b>Submission of the proposal at the national level</b>                     | Not required  |
| <b>Submission of other information at the national level</b>                | If proposal is granted Lithuanian partner must submit the detailed budget for the project implementation prior to the grant agreement signature.  |
| <b>Submission of financial and scientific reports at the national level</b> | Quarterly and yearly financial reports and two (2) scientific reports (mid-term and final) are required.  |
| <b>Further guidance</b>   | Please contact National contact person and consult national call text and the webpage <a href="https://www.lmt.lt/lt/mokslo-finansavimas/euopos-partnerystes-era-net-ir-kitos-koordinavimo-veiklos/era4health/4057">https://www.lmt.lt/lt/mokslo-finansavimas/euopos-partnerystes-era-net-ir-kitos-koordinavimo-veiklos/era4health/4057</a>   |

|  |  |
|--|--|
| <b>Country</b>   | <b>Norway</b>  |
| <b>Funding organisation</b>  | <b>Research Council of Norway</b>  |
| <b>National contact person</b>   | Henrietta Blankson<br><a href="mailto:hbl@rcn.no">hbl@rcn.no</a><br>+47 92233762   |
| <b>Funding commitment</b>  | 600 000 euro   |
| <b>Anticipated number of fundable proposals</b>                        | 1-2  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | If the Norwegian participant is a partner, maximum budget is 300 000 €<br>If the Norwegian participant has a coordinator role, maximum budget is 400.000 €.<br><br>Total budget for Norwegian partners in a single project is 400 000 €.   |
| <b>Eligibility of partners</b>   | Norwegian universities, university colleges, hospitals, research institutes, public sector, SME and other private industry.<br><br>The Research Council cannot award support to an enterprise that is defined as an "undertaking in difficulty" under the state aid rules (see the " <a href="#">Definition of 'undertaking in difficulty' on our website</a> ").<br><br>"Enkeltpersonforetak", that is Norwegian companies with sole proprietorship, cannot participate as coordinator.   |
| <b>Eligibility of costs, types and their caps</b>                      |  |
| <b>Submission of the proposal at the national level</b>                | Payroll expenses, procurement of R&D services, consumables, network measures. The <a href="#">RCN research project budget rules</a> should be followed. However, PhD fellowships are not eligible within the RCN funding and if a postdoc fellowship is included, it must be sought for 2 years<br><br>The overhead cost is included in the rates for personnel.<br><br>SME or other industrial partner is funded with up to 50 % of their eligible project costs. Se details in <a href="#">the State aid rules</a><br><br>For funded projects, the contractual budget will be in NOK using the exchange rate from the pre-proposal deadline. |
| <b>Submission of other information at the national level</b>           | If the proposal is granted, information about national registration will be given.   |

|   |                |
|---|----------------|
| <b>Submission of financial and scientific reports at the national level</b> | No             |
| <b>Further guidance</b>   | Yes, if funded |

|  |  |
|--|--|
| <b>Country</b>   | <b>Poland</b>  |
| <b>Funding organisation</b>  | <b>National Centre for Research and Development</b>  |
| <b>National contact person</b>   | <p>Dr Marcin Chmielewski<br/> T: +48 22 39 07 109<br/> M: +48 571 226 666<br/> <a href="mailto:marcin.chmielewski@ncbr.gov.pl">marcin.chmielewski@ncbr.gov.pl</a></p> <p>Mateusz Skutnik<br/> T: +48 22 39 07 148<br/> M: +48 515 339 175<br/> <a href="mailto:mateusz.skutnik@ncbr.gov.pl">mateusz.skutnik@ncbr.gov.pl</a></p> <p>Department of International Cooperation,<br/> ul. Chmielna 69, 00-801 Warszawa, Poland</p>  |
| <b>Funding commitment</b>  | 1 250 000 €  |
| <b>Anticipated number of fundable proposals</b>                        | 3  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | 400 000 € per project  |
| <b>Eligibility of partners</b>   | <p>Following entities are eligible to apply:</p> <ul style="list-style-type: none"> <li>• Micro, Small, Medium and Large enterprise;</li> <li>• Research organisation;</li> <li>• Group of entities (within the meaning of art. 37 section 1, point 1a of The Act of 30 April 2010 on the National Centre for Research and Development, published in Journal of Laws item 2279, 2022;).</li> </ul> <p>Entity must be registered in Poland;</p> <ul style="list-style-type: none"> <li>• For enterprises it is strongly advised to state in the Pre-proposal application form the KRS number of the enterprise and the size of the enterprise (micro/small, medium, large);</li> <li>• A condition for the participation of a group of entities as the Applicant in the competition is its formal existence on the date of submission of the pre-proposal, confirmed by its members concluding, at least conditionally, agreement on the creation of a group of entities;</li> </ul> <p>Please note that group of entities counts as at least two project partners from Poland (it meets the limit on the number of participants from the same country, please refer to call text for details).</p> |
| <b>Eligibility of costs, types and their caps</b>                      | The eligible costs shall be the following:   |

|  | <p>1. <b>personnel costs</b> (researchers, technicians and other supporting staff to the extent employed on the research project);</p> <p>2. <b>operating costs</b> including costs of instruments, equipment, technical knowledge, patents, costs for buildings and land, costs of materials, supplies and similar products incurred directly as a result of the research activity.</p> <p>3. <b>cost of contractual research</b>, costs of consultancy and equivalent services used exclusively for the research activity; this cost type cannot account for more than 70% of all eligible costs of a project; the subcontracting can be obtained from consortium partner only in justified case, this need will be verified by a national expert panel.</p> <p>4. <b>additional overheads</b> incurred indirectly as a result of the research project; that costs are exactly 25% of eligible project costs and are counted as a multiplication by percentage given above and the rest of direct costs, excluding subcontracting (3); It means <math>4 = (1+2) * 25\%</math>.</p> <p>Funding quota of Polish participants can be up to 100% for research organisations. In the case of enterprises, funding quota will be decided on a case-by-case basis depending on the size of the company, type of research/development, risk associated with the research activities and commercial perspective of exploitation, under the Regulation of the Minister of Science and Higher Education of 19 August 2020 on criteria and rules on granting state aid by the National Centre for Research and Development, published in Journal of Laws item 1456, 2020.</p> <table border="1" data-bbox="504 1137 1410 1615"> <thead> <tr> <th></th> <th>Large Enterprises</th> <th>Medium Enterprises</th> <th>Small Enterprises</th> <th>Research organizations</th> </tr> </thead> <tbody> <tr> <td><b>Fundamental/Basic Research</b></td> <td>Not eligible</td> <td>Not eligible</td> <td>Not eligible</td> <td>Not eligible</td> </tr> <tr> <td><b>Industrial/Applied Research</b></td> <td>Up to 50+15 (max 65 %)</td> <td>Up to 50+10+15 (max 75 %)</td> <td>Up to 50+20+15 (max 80 %)</td> <td>Up to 100 %</td> </tr> <tr> <td><b>Experimental development</b></td> <td>Up to 25+15 (max 40 %)</td> <td>Up to 25+10+15 (max 50 %)</td> <td>Up to 25+20+15 (max 60 %)</td> <td>Up to 100 %</td> </tr> </tbody> </table> <p>Only Industrial/Applied Research and Experimental Development will be funded. Other type of activities (e.g. coordination, dissemination, management) is not eligible for funding as separate research tasks in the project schedule.</p> |                           | Large Enterprises         | Medium Enterprises     | Small Enterprises | Research organizations | <b>Fundamental/Basic Research</b> | Not eligible | Not eligible | Not eligible | Not eligible | <b>Industrial/Applied Research</b> | Up to 50+15 (max 65 %) | Up to 50+10+15 (max 75 %) | Up to 50+20+15 (max 80 %) | Up to 100 % | <b>Experimental development</b> | Up to 25+15 (max 40 %) | Up to 25+10+15 (max 50 %) | Up to 25+20+15 (max 60 %) | Up to 100 % |
|--|---|---------------------------|---------------------------|------------------------|-------------------|------------------------|-----------------------------------|--------------|--------------|--------------|--------------|------------------------------------|------------------------|---------------------------|---------------------------|-------------|---------------------------------|------------------------|---------------------------|---------------------------|-------------|
|  | Large Enterprises   | Medium Enterprises        | Small Enterprises         | Research organizations |                   |                        |                                   |              |              |              |              |                                    |                        |                           |                           |             |                                 |                        |                           |                           |             |
| <b>Fundamental/Basic Research</b>                              | Not eligible  | Not eligible              | Not eligible              | Not eligible           |                   |                        |                                   |              |              |              |              |                                    |                        |                           |                           |             |                                 |                        |                           |                           |             |
| <b>Industrial/Applied Research</b>                             | Up to 50+15 (max 65 %)  | Up to 50+10+15 (max 75 %) | Up to 50+20+15 (max 80 %) | Up to 100 %            |                   |                        |                                   |              |              |              |              |                                    |                        |                           |                           |             |                                 |                        |                           |                           |             |
| <b>Experimental development</b>                                | Up to 25+15 (max 40 %)  | Up to 25+10+15 (max 50 %) | Up to 25+20+15 (max 60 %) | Up to 100 %            |                   |                        |                                   |              |              |              |              |                                    |                        |                           |                           |             |                                 |                        |                           |                           |             |
| <p><b>Submission of the proposal at the national level</b></p> | <p>Polish Participants will be informed and invited to submit Polish proposal once the international evaluation and the ranking list will be established.</p>   |                           |                           |                        |                   |                        |                                   |              |              |              |              |                                    |                        |                           |                           |             |                                 |                        |                           |                           |             |

|   |  |
|---|--|
| <b>Submission of other information at the national level</b>                | -  |
| <b>Submission of financial and scientific reports at the national level</b> | Annual scientific reports are obligatory.  |
| <b>Further guidance</b>   | <p>Sample documents are available at:<br/> <a href="https://www.gov.pl/web/ncbr/wniosek-krajowy">https://www.gov.pl/web/ncbr/wniosek-krajowy</a></p> <p>We encourage you to learn about and use our "PartFinder" (Partner Search Tool), which allows you to match science and industry entities from around the World with each other. The search engine is available at:<br/> <a href="https://partfinder.ncbr.gov.pl/">https://partfinder.ncbr.gov.pl/</a></p> |

|  |  |
|--|--|
| <b>Country</b>   | <b>Romania</b>   |
| <b>Funding organisation</b>  | <b>Executive Agency for Higher Education, Research, Development and Innovation Funding</b>   |
| <b>National contact person</b>   | <p>Mihaela Manole</p> <p>E-mail: <a href="mailto:mihaela.manole@uefiscdi.ro">mihaela.manole@uefiscdi.ro</a></p> <p>Phone: +40 21 302 38 63</p> <p>Nicoleta Dumitrache</p> <p>E-mail: <a href="mailto:nicoleta.dumitrache@uefiscdi.ro">nicoleta.dumitrache@uefiscdi.ro</a></p> <p>Phone: +40 21 302 38 86</p>   |
| <b>Funding commitment</b>  | 1.000.000 euro   |
| <b>Anticipated number of fundable proposals</b>                        | 4-5  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | <p>Funding rates vary in accordance with state aid legislation.</p> <p>For more information :</p> <p><a href="https://uefiscdi.ro/pachet-de-informatii-suprogramul-3-2-orizont-2020">https://uefiscdi.ro/pachet-de-informatii-suprogramul-3-2-orizont-2020</a></p> <ul style="list-style-type: none"> <li>• 250.000 euro for all romanian partners in case a Romanian institution is the Coordinator;</li> <li>• 200.000 for all romanian partners in case a Romanian institution is not the Coordinator.</li> </ul>   |
| <b>Eligibility of partners</b>   | Eligible entities for funding are universities, public institutions, R&D national institutions, joint-stock companies, SME's and Large companies, NGOs (associations, foundations, etc.), others.  |
| <b>Eligibility of costs, types and their caps</b>                      | <p>a. Staff costs;</p> <p>b. Logistics expenses</p> <ul style="list-style-type: none"> <li>- Capital expenditure;</li> <li>- Expenditure on stocks - supplies and inventory items;</li> <li>- Expenditure on services performed by third parties cannot exceed 25 % of the funding from the public budget. The subcontracted parts should not be core/substantial parts of the project work;</li> </ul> <p>c. Travel expenses;</p> <p>d. Overhead (indirect costs) is calculated as a percentage of direct costs: staff costs, logistics costs (excluding capital costs and cost for subcontracting) and travel expenses. Indirect costs will not exceed 20 % of direct costs.</p> |

|   |                                    |                          |                           |                          |  |
|---|------------------------------------|--------------------------|---------------------------|--------------------------|--|
| <b>Submission of the proposal at the national level</b>                     | no                                 |                          |                           |                          |  |
| <b>Submission of other information at the national level</b>                | no                                 |                          |                           |                          |  |
| <b>Submission of financial and scientific reports at the national level</b> | no                                 |                          |                           |                          |  |
| <b>Further guidance</b>   | Maximum funding percentages:       |                          |                           |                          |  |
|   | <b>Type of research</b>            | <b>Large Enterprises</b> | <b>Medium Enterprises</b> | <b>Small Enterprises</b> | <b>Universities and research organisations</b> |
|   | <b>Fundamental/Basic Research</b>  | 100                      | 100                       | 100                      | 100  |
|   | <b>Industrial/Applied Research</b> | Up to 50+15 (max 65)     | Up to 60+15 (max 75%)     | Up to 70+10 (max 85)     | 100  |
| <b>Experimental development</b>   | Up to 25+15 (max 40)               | Up to 35+15 (max 50)     | Up to 40+15 (max 65)      | 100                      |  |

|  |   |
|--|---|
| <b>Country</b>   | <b>Slovakia</b>   |
| <b>Funding organisation</b>  | <b>Slovak Academy of Sciences</b>   |
| <b>National contact person</b>   | Katarina Bibova<br><a href="mailto:bibova@up.upsav.sk">bibova@up.upsav.sk</a>   |
| <b>Funding commitment</b>  | 240.000€  |
| <b>Anticipated number of fundable proposals</b>                        | 2   |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | Up to 120.000€ per project  |
| <b>Eligibility of partners</b>   | <p>Only research Institutes of the Slovak Academy of Sciences are eligible organisations for funding by SAS (up to 100%).</p> <ol style="list-style-type: none"> <li>1. The Slovak principal investigator must have a job contract for more than 50% working hours in the SAS organization for which the project proposal or participation in the project proposal is submitted.</li> <li>2. Other researchers, except for doctoral students, must have a working relationship with the SAS organization.</li> <li>3. Each researcher of the Slovak partner research team of a project consortium (other than the Slovak Principal Investigator) must have a job contract with or a fellowship with the Slovak Principal Investigator, lasting until the end of the project or beyond.</li> </ol> |
| <b>Eligibility of costs, types and their caps</b>                      | <p>Total eligible costs = Permanent salaries + Other costs (DC + IC)</p> <ul style="list-style-type: none"> <li>•Permanent salaries 45 000 € (36 months)</li> <li>•Other costs: 75 000 € (36 months)</li> </ul> <p>Direct costs (DC): Personnel (max. 15% of DC), Consumables, Equipment (max. 40% of DC) and Travel costs</p> <p>Indirect costs (IC, Overheads): max. 20 % of DC.</p> <p>Limitations and specifications are available: (<a href="#">Financial rules for awarding SAS grants for international research projects</a>)</p>   |
| <b>Submission of the proposal at the national level</b>                | <p>Submission of the proposal at the national level will be required once the international evaluation has taken place and the ranking list has been endorsed by the Joint Call Steering Committee (CSC). The Slovak partner will be informed about recommendation for funding by the project consortium coordinator and invited by SAS <b>to submit the national proposal form (MVTs form)</b>. The Presidium of SAS makes the final decision concerning the approval of funding (according to internal rules of SAS).</p>   |
| <b>Submission of other information at the national level</b>           | -   |

|   |   |
|---|---|
| <b>Submission of financial and scientific reports at the national level</b> | Annual financial report during the duration of the funded project |
| <b>Further guidance</b>   |   |

|  |   |
|--|---|
| <b>Country</b>   | <b>Spain</b>  |
| <b>Funding organisation</b>  | <b>Consejería de Salud y Consumo de la Junta de Andalucía</b>   |
| <b>National contact person</b>   | Alicia Milano Curto<br>Tel: +34 955040450<br>email <a href="mailto:convocatorias.fps@juntadeandalucia.es">convocatorias.fps@juntadeandalucia.es</a>   |
| <b>Funding commitment</b>  | 250.000,00 €  |
| <b>Anticipated number of fundable proposals</b>                        | 1-2   |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | 125.000€, 250.000€ if coordinator (including 21% indirect costs)  |
| <b>Eligibility of partners</b>   | <p>Eligibility criteria established in <a href="#">Orden de 10 de agosto de 2023</a> de la Consejería de Salud y Consumo de la Junta de Andalucía.</p> <ul style="list-style-type: none"> <li>• Eligible organisation must be Andalusian Non-profit entities registered as Agents of the Andalusian Knowledge System (Registro de Agentes Andaluces del Conocimiento) with research and innovation activity in Biomedicine and Health Sciences, ie: Research managing foundations of the Andalusian Public Health System</li> <li>• Principal investigators must be linked through a civil servant, statutory or labour relationship with the applicant or performing centre. For Health Research Institutes (Institutos de Investigación Sanitaria, IIS), the link may be with any of the public or private law entities that are part of the IIS provided that the entity meets all the specific requirements determined in each action, and, in any case, be personnel assigned to the IIS.</li> <li>• More than one partner from Andalusia may participate in the same project</li> <li>• A PI can only participate in one application per call.</li> <li>• For receiving regional funding, the final funding decision issued by the corresponding program's decision-making body must be accredited</li> <li>• The duration of the projects shall be determined by the corresponding JTC. In any case, this period shall be stated in the award resolution.</li> </ul> |
| <b>Eligibility of costs, types and their caps</b>                      | <ol style="list-style-type: none"> <li>a. Goods and services: consumables, bibliographic material, equipment rentals, software licenses and external services.</li> <li>b. Personnel costs: specifically hired for the project, including salaries, employer Social Security contributions, legally established compensation and other duly justified expenses derived.</li> </ol>  |

|  |   |
|--|---|
|  | <p>c. Travel, accommodation and subsistence according to the maximum amounts of compensation for service established in Decree 54/1989, of March 21, on compensation for service of the Junta de Andalucía, exclusively for people who are part of the research group or hired under the funded project. Exceptionally, any expense outside these amounts, or for people other than those listed before, must be authorised by the granting body.</p> <p>d. Registration fees for congresses or conferences for the presentation and dissemination of the results. Publication costs</p> <p>e. Other expenses duly justified and necessary for carrying out the project.</p> <p>f. Indirect costs 21%</p> <p>g. Subcontracting costs: cannot exceed 50% of the funding and need prior authorization from the granting body. Nor Scientific aspects nor the management of the project should be subcontracted.</p> <p>The following are not considered eligible expenses</p> <ul style="list-style-type: none"> <li>- Equipment or Equipment repair and maintenance</li> <li>- Items or amounts that, after analysis, are not considered justified</li> <li>- Amounts paid to persons participating in the project, with the exception of expenses necessary for special attention to patients that involve compensation for their participation in the project not derived from an employment relationship.</li> </ul> <p>The sum of the funding or income received for the same purpose may in no case exceed the cost of the funded activity.</p> |
| <p><b>Submission of the proposal at the national level</b></p>                     | <ul style="list-style-type: none"> <li>• Regional applications must be submitted to the General Secretariat of Public Health and R&amp;D&amp;I in Health exclusively by telematic means (please see section 10.c <a href="#">Orden de 10 de agosto de 2023</a>)</li> <li>• The deadline for the submission of regional applications will be established in the regional call and will be informed through the website of the Regional Ministry of Health and Consumer Affairs.</li> </ul>   |
| <p><b>Submission of other information at the national level</b></p>                | <p>The documents to be provided are detailed in section 14 of the <a href="#">Orden de 10 de agosto de 2023</a>)</p> <p>For projects involving invasive procedures on human beings, their biological material and/or clinical data, a favourable report or a document accrediting the request for its evaluation by the Biomedical Research Ethics Committee has to be provided</p>   |
| <p><b>Submission of financial and scientific reports at the national level</b></p> | <p>Beneficiaries must submit financial and scientific reports to Consejería de Salud y Consumo de la Junta de Andalucía (please see section 22.b) 3º and 25.f) 1º <a href="#">Orden de 10 de agosto de 2023</a>)</p>  |

**Further guidance**

The projects must respect the fundamental principles established in national and international declarations, protocols and conventions on research ethics, as well as respect the requirements established in national and regional legislation in the field of biomedical research, development and innovation, personal data protection and bioethics.

When the results are not susceptible to protection of industrial or intellectual property rights, the scientific publications resulting from the funding granted must be made available in open access, in accordance with article 37 of Law 14/2011, of June 1.

|  |   |
|--|---|
| <b>Country</b>   | Spain   |
| <b>Funding organisation</b>  | Institute of Health Carlos III (Instituto de Salud Carlos III- ISCIII)  |
| <b>National contact person</b>   | Sara García Rodríguez<br>E-mail: <a href="mailto:sara.garcia@isciii.es">sara.garcia@isciii.es</a><br>Phone: (+34) 91 822 28 68  |
| <b>Funding commitment</b>  | National Programme: Acción Estratégica en Salud (AES 2024)<br>400.000 € (pending of approval of Spanish State Budget)   |
| <b>Anticipated number of fundable proposals</b>                        | 2-3 projects  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | <p><b>Maximum funding from ISCIII per awarded Spanish project :</b></p> <ul style="list-style-type: none"> <li>• If a Spanish Partner requesting funding to the ISCIII is <b>NOT</b> the Coordinator of the transnational project: <ul style="list-style-type: none"> <li>• <b>140.000€</b> (overheads included), if there is only one Spanish Partner requesting funding to the ISCIII in the proposal.</li> <li>• <b>180.000€</b> (overheads included), if there are two Spanish Partners requesting funding to the ISCIII in the proposal.</li> </ul> </li> <li>• If a Spanish Partner requesting funding to the ISCIII <b>IS</b> the Coordinator of the transnational project: <ul style="list-style-type: none"> <li>• <b>200.000€</b> (overheads included), if there is only one Spanish Partner in the proposal, acting as a coordinator.</li> <li>• <b>250.000€</b> (overheads included), if there is one Spanish Partner in addition to the Spanish Coordinator in the proposal, both requesting funding to the ISCIII.</li> </ul> </li> </ul> <p>Overheads according to AES 2024: 25%</p> <p><b>Projects' duration:</b> from 24 months to 36 months</p> <p>The level of funding will take into account the evaluation of the collaborative proposal, the scientific quality of the Spanish group, the added value of the international collaboration, the participation of the primary health care and the financial resources available.</p> |
| <b>Eligibility of partners</b>   | <p>A maximum of two different partners requesting funding from ISCIII may participate in the same project proposal.</p> <p>The participation of the <b>Spanish primary health care</b> is crucial to the success of this call so for that:</p>  |

- The participation in the consortium of at least one Spanish primary health care center is mandatory in this call. **Proposals without a Spanish primary health care center will not be eligible.**

- Therefore, only projects with at least one Principal Investigator (PI) **belonging to an** (assigned/affiliated) primary care center participates **will be** eligible for funding.

- In the event that the corresponding primary care center forms an integral part of an Accredited Health Research Institute (IIS) and the **PI belongs to** (assigned/affiliated) the IIS, the eligible institution will be the Institute.

**Eligible institutions:**

- **Accredited Health Research Institutes** (Institutos de Investigación Sanitaria acreditados, IIS). Accredited according to the RD 279/2016 (These institutions may manage research via a foundation regulated according to the Spanish Act 50/ 2002, of December 26th). See the list of IIS in [this link](#).

- **Hospitals or public health administration of the Spanish National Health System (SNS)** These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation's statutes may be submitted).

- **CIBER** team members applying to the call must be from at least two groups belonging to CIBER in two different home institutions and one of these two should be a hospital, primary health care or public health administration of the Spanish National Health System (SNS) or Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS). Please contact Cristina Rodríguez ([cristina.rodriguez@ciberisciii.es](mailto:cristina.rodriguez@ciberisciii.es)) for more information related to CIBER's eligibility.

- **Public Research Institutions (OPIs)** as defined in article 47 of Law 14/2011, of 1 June, in accordance with the provisions of Royal Decree 202/2021, of 30 March, **Private health entities and institutions, public Universities and private Universities with proven R&D activity capacity, other public R&D centres.**

- Applicants from ISCIII are also eligible as Public Research Institution (OPI). Eligibility criteria from AESI 2024 apply.

- **Spanish Primary health care** will be eligible institutions even if they apply independently. This would also apply in the case that the PI from CIBER or from the Accredited Health Research Institutes (IIS) belongs to primary health care.

|  |   |
|--|---|
|  | <p><b>NOT eligible institutions:</b></p> <ul style="list-style-type: none"> <li>- Those declared by AES 2024 as ineligible to receive funds by ISCIII.</li> <li>- Particularly for this call, it will not be eligible the <b>National Technological Centres</b> and National Centres for supporting technological innovation that are inscribed in the Register according by RD 2093/2008, of 19 December.</li> </ul>   |
| <p><b>Eligibility of PI and team members</b></p>         | <ul style="list-style-type: none"> <li>• Principal Investigators (PI) shall mandatory have <b>PhD degree</b>.</li> <li>• Principal Investigators (PI) can only participate in one project proposal per call.</li> <li>• Principal Investigators (PIs) belonging to an <b>Accredited Health Research Institutes (IIS)</b> could apply <b>only from the IIS</b>.</li> <li>• The Principal Investigator (PI) and all members of the research group must belong to the eligible institutions in the call.</li> <li>• Only one PI per beneficiary institution may be funded within the same proposal.</li> <li>• PIs that has an ongoing International Collaboration (PCIN) project of the same initiative and purpose that this call and that the project has an ending date after the 31st December 2024 will not be able to apply for this call. This incompatibility will affect only to the PI. And this incompatibility will not apply in the case that the PI participate as coordinator in the new application or in the ongoing project.</li> </ul> <p>For additional incompatibilities please review AES 2024.</p> <p><b>Excluded</b> personnel as Principal Investigator (PI):</p> <ul style="list-style-type: none"> <li>• Those undergoing a postgraduate training in Health Specialization (MIR, EIR, FIR, QIR, BIR, PIR, RFIR).</li> <li>• Those undergoing research training (e.g. PhD students, or “Río Hortega” contracts).</li> <li>• Those undergoing postdoctoral training (e.g. “Sara Borrell” or “Juan de la Cierva” contracts).</li> <li>• Researchers contracted by a RICORs and platforms funded by ISCIII.</li> </ul> |
| <p><b>Eligibility of costs, types and their caps</b></p> | <ul style="list-style-type: none"> <li>• <b>Personnel costs:</b></li> </ul>   |

|  |   |
|--|---|
|  | <ul style="list-style-type: none"> <li>- Personnel costs will be eligible for contracts with the needed professional category (superior technician, BSc (grado), MSc (máster), PhD (doctor) for the project development accordingly to the published salary tables in ISCIII's webpage / AES2024.</li> <li>- Contracts for PhD students will be done in the framework of National Subprogramme for Training (scholarships are not eligible).</li> <li>- Personnel costs will NOT be eligible when they correspond to civil servants or the equivalent personnel (as specified in the Art. 3.4 of AES2024) either employed by the beneficiary entities or belonging to the research team.</li> <li>- Personnel costs will be eligible when corresponding to contracts under the frame of Art. 23bis of Law 14/2011, 1<sup>st</sup> June, following the specifications established in AES2024.</li> <li>• <b>Other eligible costs:</b> Current costs, small scientific equipment, disposable materials, travelling expenses, complementary expenses (use of central and general research support services of the beneficiary entity), publication and dissemination of results and other costs as included in AES 2024 that can be justified as necessary to carry out the proposed activities.</li> <li>• <b>Overheads</b>, according to AES 2024 (25%)</li> <li>• <b>Double funding of the same concept is not allowed.</b></li> <li>• National applications will be required by ISCIII.</li> </ul> |
| <p><b>Submission of the proposal at the national level</b></p>                     | <p>Due to administrative and legal regulations, the Institute of Health Carlos III establishes the <b>31<sup>st</sup> October 2024</b> as the national deadline for the decision on fundable project consortia which includes Spanish partners to be funded by ISCIII, which must present their national application in the period stated in AES 2024.</p> <p>Any concerned applicant in a proposal for which no final decision has been made by the deadline of <b>31/10/2024</b>, could be declared not fundable by ISCIII.</p>   |
| <p><b>Submission of other information at the national level</b></p>                | <p>As specified by AES 2024.</p>  |
| <p><b>Submission of financial and scientific reports at the national level</b></p> | <p>As specified by ISCIII's instructions (please check ISCIII's webpage).</p>   |
| <p><b>Submission of a pre-eligibility form needed at national level</b></p>        | <p>In order to expedite the eligibility check process, it is mandatory that all the applicants submit the CVA-ISCIII of the PI and, if applicable, the</p>  |

|   |   |
|---|---|
|   | <p>certification of the legal link of the PI with a primary health care center. This certification shall be signed electronically by the legal representative of their Entity.</p> <p>A template of this certificate for the PI of primary health care can be downloaded here:<br/> <a href="#">Certificado Vinculación IP AtencionPrimaria</a></p> <p>These documents shall be submitted by the PI by electronic email before the proposal submission deadline to: <a href="mailto:sara.garcia@isciii.es">sara.garcia@isciii.es</a></p>  |
| <p><b>Requirements on data and repositories</b></p>         | <ul style="list-style-type: none"> <li>• Researchers funded by ISCIII must make public the human genomic data, as well as relevant data (phenotype and exposition data) generated inside the funded project and will use open access repositories. Researchers must also make public all the necessary information for the interpretation of these genomic data, including lab protocols, data instruments survey tools. Regarding genomic data it is understood: association of complete genomes (GWAS), matrixes of polymorphism of a single nucleotide (SNP) and sequence of genome, and transcriptomic, metagenomic, epigenomic and gene expression data. The researchers whose projects are funded by ISCIII are recommended to store their scientific data at the "<a href="#">ELIXIR Core Data Resources</a>", or if non-European repositories or data bases are to be used they must be certified by ELIXIR or the US National Center for Biotechnology Information (NCBI).</li> <li>• ISCIII may not fund any project that may require a repository and/or a data base without a plan ensuring sustainability and decommissioning after the end of funding.</li> </ul> |
| <p><b>Requirements for clinical studies</b></p>             | <p>Spanish groups that are involved on the performance of a clinical trial in the proposal, <b>are recommended to include</b> in their team a member from their scientific node of the EU Clinical Trials Network (SCReN or ECRIN-ERIC) or if it does not exist, a member from the personnel of their Clinical Research Supporting Platform of their institutions (UIC).</p>  |
| <p><b>Use of Research infrastructures and platforms</b></p> | <p>Researchers funded by ISCIII are encouraged to make use of the resources available through the European Research Infrastructures and the Spanish Platforms funded by ISCIII for supporting the biomedical and health R&amp;I.</p>  |
| <p><b>Acknowledgements</b></p>                              | <p>Any publication, data base, product or event protected with IPR or not, resulting from the granted project must acknowledge "Award no. XX by Instituto de Salud Carlos III (ISCIII) through AES 2024 and within the ERA4Health Partnership" even after the end of the project, including other specific acknowledgments that could be requested by ISCIII to the granted project. For more information please see ISCIII's <a href="#">ROR</a> here.</p>   |

**Further guidance**

|  |   |
|--|---|
| <b>Country/Region</b>  | <b>Spain/Asturias</b>   |
| <b>Funding organisation</b>  | <b>SEKUENS - FICYT</b>  |
| <b>National/regional contact person</b>                                | Ana Elena Fernández - <a href="mailto:anae@sekuens.es">anae@sekuens.es</a><br>Floriane Nguyen – <a href="mailto:fnguyen@ficyt.es">fnguyen@ficyt.es</a>  |
| <b>Funding commitment</b>  | €250.000  |
| <b>Anticipated number of fundable proposals</b>                        | Expected: 2-3 project   |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | Maximum: €150.000 per partner and per project<br>Expected: €80.000 - 100.000  |
| <b>Eligibility of partners</b>   | <ul style="list-style-type: none"> <li>• University of Oviedo</li> <li>• Hospitals and primary health care centers of the Asturias Health System.</li> <li>• Accredited Health Research Institutes located in Asturias, or the foundation in charge of managing the research of these Institutes</li> <li>• Public or Private Research and Technology Organisations located in Asturias.</li> <li>• Micro, small, medium and large enterprises located in Asturias.</li> </ul>  |
| <b>Eligibility of costs, types and their caps</b>                      | <p>The following costs are eligible if related to the project:</p> <ul style="list-style-type: none"> <li>• Personnel costs: new researchers and/or technicians hired for the project.</li> <li>• Only companies: own staff (excluding social security costs): researchers and technicians. Supporting staff only in case of coordination of the proposal.</li> <li>• Costs of materials and supplies.</li> <li>• Costs of contractual research, knowledge, patents and consultancy services.</li> <li>• International travel and accommodation costs.</li> <li>• Other direct costs, like audit fees</li> </ul> <p>Minimum budget : €100.000</p> |
| <b>Submission of the proposal at the national/regional level</b>       | The applicants will have to submit a proposal at regional level, meeting all the requirements of the regional call.   |

|  |   |
|--|---|
| <b>Submission of other information at the national/regional level</b>                | It will be indicated in the regional call.  |
| <b>Submission of financial and scientific reports at the national/regional level</b> | The applicants will have to submit annual financial and scientific reports at regional level. |
| <b>Further guidance</b>  | Yearly calls.<br>Actual funding programme under revision.                                     |

|  |  |
|--|--|
| <b>Country</b>   | <b>Switzerland</b>   |
| <b>Funding organisation</b>  | <b>Swiss National Science Foundation (SNSF)</b>  |
| <b>National contact person</b>   | Elisa Manetti & Selina Niggli<br><a href="mailto:era4health@snf.ch">era4health@snf.ch</a>  |
| <b>Funding commitment</b>  | 1'500'000 CHF (approximately 1'500'000 EUR)  |
| <b>Anticipated number of fundable proposals</b>                        | 3-4  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | <p>The SNSF provides a <b>minimum grant of 100'000 Swiss francs per project</b>. The SNSF provides a <b>maximum of 250,000 Swiss francs annually per applicant</b> of a project and a maximum of 1 million Swiss francs annually for the project as a whole (SNSF-funded part).</p> <p>Applicants should bear in mind that <b>the SNSF anticipates funding between 3 and 4 projects</b> under this call.</p>   |
| <b>Eligibility of partners</b>   | <p>Applicants must comply with the <a href="#">SNSF Funding Regulations</a>.</p> <p><b>Participation of Swiss-based partners requesting financial support from the SNSF is restricted to one project</b> (Art.6.3, <a href="#">SNSF Regulations on project funding</a>). They may, however, participate in other consortia projects as self-financed partners.</p> <p>The maximum number of grants in the project funding scheme for the same funding period from the SNSF is limited to three grants, provided that at least one grant is for an EU consortium project or has been granted on the basis of a lead agency, Weave or International Co-investigator scheme evaluation. <b>Swiss-based investigators who already hold three SNSF grants in project funding cannot request financial support from the SNSF to participate in this call</b> (Article 13 of <a href="#">the Amended Project Funding Regulations</a>).</p> <p><b>Proposals with overlapping funding periods with ongoing SNSF projects</b> are only approved if the research projects pursue different goals (Article 17 of <a href="#">the SNSF Funding Regulations</a>).</p> <p><b>The SNSF exclusively funds research conducted for purposes that are not directly commercial.</b> Pursuant to the Research and Innovation Promotion Act RIPA and the legal framework of the SNSF, no research grants are awarded if the relevant research is conducted for directly commercial purposes or if the persons involved in the research work do not enjoy scientific independence.</p> |
| <b>Eligibility of costs, types and their caps</b>                      | <b>Eligible costs</b> are outlined in the <a href="#">SNSF Funding Regulations</a> (Art. 28) and the <a href="#">SNSF General Implementation Regulations</a> (Section 2).  |

|  |   |
|--|---|
|  | <p><b>Project overhead costs cannot be applied for.</b> They are calculated on the basis of the research funding acquired by eligible institutions under eligible funding schemes. Overhead contributions are paid in retrospect at a flat rate to the institutions of the SNSF awardees.</p>   |
| <p><b>Submission of the proposal at the national level</b></p>                     | <p><b>Mandatory, parallel submission of pre- and full-proposal via mySNF</b></p> <p>Swiss-based partners must submit pre-proposals and full proposals <b>via mySNF</b> at the same submission deadline than the consortium application. These submissions are mandatory and do not replace the submission of the consortium application to the Call Secretariat.</p> <p><b>Pre-proposal</b> forms are created by selecting "Projects: Partnership: ERA4Health: Pre-proposal".</p> <p><b>Full-proposal</b> forms are created by selecting "Projects: Partnership: ERA4Health: Full proposal" and are to be linked to the pre-proposal by selecting its number in the data container "Relation to pre-proposal".</p> <p><b>In case of multiple, Swiss-based partners participating in the same consortium,</b> only one application is to be submitted on mySNF, whereby one Swiss-based partner must act as "corresponding applicant" and the other Swiss-based partners are to be listed as "other applicants".</p> <p><b>International partners of the consortium</b> applying for funding at different funding agencies from the SNSF cannot be declared as "project partners" in the sense of article 11.2 of the SNSF Funding Regulations. For the submission via mySNF, they are to be declared as "consortium partners" instead and must apply for their funding at their respective research funding organisation.</p> |
| <p><b>Submission of other information at the national level</b></p>                | <p><b>Data management plan</b></p> <p>Applicants will have to complete the DMP on mySNF once the project is approved, regardless of whether a DMP is requested by the consortium. The DMP has to cover the research data, which are collected, observed, generated or reused in the Swiss part of the project and has to comply with the <a href="#">SNSF Open Research Data Policy</a>.</p>  |
| <p><b>Submission of financial and scientific reports at the national level</b></p> | <p>Yearly, <b>financial reports</b> must be submitted to the SNSF via mySNF.</p> <p>As <b>final scientific report</b>, the SNSF requests the submission of the final scientific report submitted to the ERA4Health Call Secretariat. No other scientific reports are requested.</p>   |
| <p><b>Further guidance</b></p>   | <p>Information available at:</p> <ul style="list-style-type: none"> <li>- <a href="#">SNSF Funding regulations</a></li> <li>- <a href="#">General Implementation Regulations</a></li> <li>- <a href="#">SNSF Regulations on Project Funding</a></li> </ul>  |

|   |   |
|---|---|
| <b>Country</b>  | <b>Taiwan</b>   |
| <b>Funding organisation</b>   | <b>National Science and Technology Council</b>  |
| <b>National contact person</b>  | Dr. Ching-Mei Tang<br>Email: <a href="mailto:cmtom@nstc.gov.tw">cmtom@nstc.gov.tw</a><br>Tel: +886-2-2737-7557  |
| <b>Funding commitment</b>   | 810,000€  |
| <b>Anticipated number of fundable proposals</b>                             | 2-3   |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b>      | -The maximum amount per year per project is €90,000.00 (about NTD3,000,000).<br>-The decision regarding the exact amount of the grant is dependent on the result of the NSTC's internal reviews.<br>-The number of grants of every principle investigator must comply with NSTC's regulation of the max number of two international cooperation projects granted by NSTC for the same duration. |
| <b>Eligibility of partners</b>  | All research institutes, universities, hospitals, public organisations in Taiwan endorsed by the National Science and Technology Council (NSTC) as eligible institutions  |
| <b>Eligibility of costs, types and their caps</b>                           | Including personnel, consumables, hosting expenses for foreign researchers, and travel expenses for international destinations-joint research & overseas studies, for more information please refer to: <a href="https://www.nstc.gov.tw/folksonomy/list/f6d5c23c-b3ce-438e-911b-12a705dbac5a?l=ch">https://www.nstc.gov.tw/folksonomy/list/f6d5c23c-b3ce-438e-911b-12a705dbac5a?l=ch</a>       |
| <b>Submission of the proposal at the national level</b>                     | No official national application is needed in the pre-proposal or full proposal phase. But must notify the national contact person in the National Science and Technology Council of your submission to the ERA4Health joint transnational call via email, together with your application as an attachment.   |
| <b>Submission of other information at the national level</b>                | -Taiwanese project partners shall submit a proposal to the NSTC for national financing after the project has been selected and approved for funding through the ERA4Health evaluation and selection process.<br>-The proposals are required to be submitted to NSTC for funding as soon as possible as the internal process of the NSTC generally takes 6 months.                               |
| <b>Submission of financial and scientific reports at the national level</b> | please refer to: <a href="https://www.nstc.gov.tw/folksonomy/list/f6d5c23c-b3ce-438e-911b-12a705dbac5a?l=ch">https://www.nstc.gov.tw/folksonomy/list/f6d5c23c-b3ce-438e-911b-12a705dbac5a?l=ch</a>  |

**Further guidance**

<https://www.nstc.gov.tw/folksonomy/rfpDetail/c1a582ae-95bc-4449-908f-590d6cb409ea?l=ch>

|  |  |
|--|--|
| <b>Country</b>   | <b>The Netherlands</b>   |
| <b>Funding organisation</b>  | <b>Dutch Research Council (NWO)</b>  |
| <b>National contact person</b>   | Dr. Dina Ripken, NWO domain Applied Engineering Science, <a href="mailto:ERA4Health@nwo.nl">ERA4Health@nwo.nl</a> , +31 30 6001 384<br>Dr. Rob Hermans, NWO domain Applied Engineering Science, <a href="mailto:ERA4Health@nwo.nl">ERA4Health@nwo.nl</a> , +31 30 6001 317   |
| <b>Funding commitment</b>  | € 1.950.000 in total   |
| <b>Anticipated number of fundable proposals</b>                        | 6  |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b> | € 325.000 (= total amount for all Dutch partners per consortium project)   |
| <b>Eligibility of partners</b>   | <p>In this National Annex an Applicant is defined as a researcher from the Netherlands applying for funding (i.e. the Dutch part of a European consortium).</p> <p>Full, associate and assistant professors, and other researchers with a comparable position* may submit an application (i.e. participate in a consortium and request NWO funding) if they have a tenured position (and therefore a paid position for an indefinite period) or a tenure track agreement at one of the following research organisations:</p> <ul style="list-style-type: none"> <li>• Universities located in the Kingdom of the Netherlands;</li> <li>• University medical centres;</li> <li>• Institutes affiliated to the Royal Netherlands Academy of Arts and Sciences (KNAW) or NWO;</li> <li>• The Netherlands Cancer Institute;</li> <li>• The Max Planck Institute for Psycholinguistics in Nijmegen;</li> <li>• Naturalis Biodiversity Center;</li> <li>• Advanced Research Centre for NanoLithography (ARCNL);</li> <li>• Princess Máxima Center.</li> </ul> <p><i>*A comparable position refers to a researcher that has a demonstrable and comparable number of years of experience in carrying out scientific research and supervising other researchers as a full, associate or assistant professor.</i></p> <p>Persons with a zero-hour employment agreement or with a contract for a limited period of time (other than a tenure track appointment) may not submit a proposal.</p> <p>It could be the case that a tenure track agreement ends before the intended completion date of the project for which funding is applied for, or that before that date, the tenured contract ends due to a researcher reaching</p> |

|  |   |
|--|---|
|  | <p>retirement age. In that case, the researcher needs to include a statement from their employer in which the organisation concerned guarantees that the project and all project members for whom funding has been requested will receive adequate supervision for the full duration of the project</p> <p>Employees with a part-time contract should guarantee adequate supervision of the project and all project members for whom funding is requested.</p> <p>An application for funding (i.e. the Dutch part of a European consortium) has a single main applicant (i.e. Dutch Partner or Coordinator in the European consortium), responsible for scientific and financial management.</p> <ul style="list-style-type: none"> <li>• <u>An applicant may only request NWO funding for one project</u> (part of a European consortium) in this call.</li> <li>• Applicants may not apply for a scientific position for themselves.</li> </ul> <p>Please note, in this call NWO only accepts <u>applicants belonging to category</u> ‘A. Academia’ and ‘B. Clinical/public health sector’ as eligible for funding, insofar as these applicants are employed at the research organisations described above in this National Annex.</p> <p>Applicants belonging to categories ‘C. Enterprises’ and ‘D. Operational stakeholders’ are not eligible for funding by NWO. If fitting in the project scope, collaboration with partner(s) from categories C and/or D is encouraged in a co-funding capacity (in cash or in kind contribution by that partner).</p> <p>See ‘Application, Eligibility criteria’ (page 9) of the call text.</p> <p>Please note, NWO does <u>not fund clinical studies</u>.</p> |
| <p><b>Eligibility of costs, types and their caps</b></p> | <p>The NWO budget modules (including the maximum amount) available for this call for proposals are listed below. Apply only for funding that is vital to realise the project.</p> <p><b>Available budget modules</b></p> <ul style="list-style-type: none"> <li>• <i>Postdoc</i> – at least 12 full-time months and at most 36 full-time months, according to UNL or NFU rates</li> <li>• <i>Research leave</i> – max. 5 months, 1 FTE, according to UNL or NFU rates</li> <li>• <i>Material costs</i> – max. € 15.000 per year per full-time scientific position (postdoc)</li> <li>• <i>Knowledge utilisation</i> - max. € 25.000</li> <li>• <i>Internationalisation</i> - max. € 25.000</li> </ul> <p>Please, note the following:</p> <ul style="list-style-type: none"> <li>• Proposals are required to have at least one personnel position of 12 full-time months.</li> <li>• For the budget module “Postdoc”, a one-off individual bench fee of € 5.000 is added on top of the salary costs to encourage the scientific career of the project employee funded by NWO.</li> </ul>   |

|   |  |
|---|--|
|   | <ul style="list-style-type: none"> <li>• PhD positions cannot be applied for in this call, due to the maximum project duration of 3 years.</li> <li>• Overhead costs are not eligible for NWO funding.</li> </ul> <p>A more detailed explanation of the budget modules and eligible costs can be found at <a href="#">[link financieringspagina invoegen]</a>.</p>   |
| <b>Submission of the proposal at the national level</b>                     | Once proposals are selected for funding, the consortia will be notified by the Joint Call Secretariat and subsequently the national granting process will be initiated by NWO.   |
| <b>Submission of other information at the national level</b>                | Applicants are required to submit a mandatory NWO budget form in the full proposal stage separately per email to <a href="mailto:ERA4Health@nwo.nl">ERA4Health@nwo.nl</a> . Please refer to the detailed explanation of NWO budget modules to see which costs are eligible for NWO funding.<br>It is recommended to use the NWO financial details form already in the pre-proposal stage to confirm eligibility of budget items.   |
| <b>Submission of financial and scientific reports at the national level</b> | Submission of financial and scientific reports at national level is required in accordance with the rules of NWO.  |
| <b>Further guidance</b>   | <p>Postdoc salary costs and Research leave are funded in accordance with the UNL or NFU salary tables applicable at the moment the grant is awarded (<a href="https://www.nwo.nl/en/funding/funding+process+explained/salary+tables">https://www.nwo.nl/en/funding/funding+process+explained/salary+tables</a>).</p> <p>The NWO Grant Rules 2017 (<a href="http://www.nwo.nl/en/nwo-grant-rules">www.nwo.nl/en/nwo-grant-rules</a>) and the Approval of funding for scientific research 2008 (<a href="http://www.nwo.nl/en/approval-funding-scientific-research-2008">www.nwo.nl/en/approval-funding-scientific-research-2008</a>) are applicable to the part of the project's budget covered by the grant from NWO. Any arrangements made regarding the part of the project's budget covered by the grant from NWO, for instance in a consortium agreement, must comply with the NWO Grant Rules 2017 and the European legislation on state aid.</p> <p>Under the Dutch General Administrative Law Act, any interested party has the right to lodge an objection to the decision taken by NWO within six weeks of the date of the decision letter. Further information about the objections procedure can be found on the NWO website: <a href="https://www.nwo.nl/en/lodging-objection">https://www.nwo.nl/en/lodging-objection</a> .</p> |

|   |  |
|---|--|
| <b>Country</b>  | <b>Türkiye</b>   |
| <b>Funding organisation</b>   | <b>The scientific and technological research council of Türkiye, TUBITAK</b>   |
| <b>National contact person</b>  | Şükran Alpdemir<br><a href="mailto:sukran.alpdemir@tubitak.gov.tr">sukran.alpdemir@tubitak.gov.tr</a>  |
| <b>Funding commitment</b>   | 600 000 Euros (TBC)  |
| <b>Anticipated number of fundable proposals</b>                             | 2-3 projects   |
| <b>Maximum/ Minimum funding per grant awarded to a project partner</b>      | Up to 275 000 Euros per project, max. 110 000 Euros for public institutions and max. 275 000 Euros for private companies with 60% funding of the eligible costs for large companies and 75% funding of the eligible costs for SMEs (TBC)   |
| <b>Eligibility of partners</b>  | For further information about application rules and procedures, please refer to the related TUBITAK website.   |
| <b>Eligibility of costs, types and their caps</b>                           | For further information about application rules and procedures, please refer to the related TUBITAK webpage.   |
| <b>Submission of the proposal at the national level</b>                     | Yes  |
| <b>Submission of other information at the national level</b>                | Yes  |
| <b>Submission of financial and scientific reports at the national level</b> | Yes  |
| <b>Further guidance</b>   | Participants from Türkiye should also submit their proposals to TUBITAK electronically via ( <a href="https://uidb-pbs.tubitak.gov.tr/">https://uidb-pbs.tubitak.gov.tr/</a> ) for the pre-proposal phase. Only the PIs from successful projects that are listed for funding after the second stage of international evaluation are required to submit their full proposals. The applications should be completed via e-signature. |